[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3109
1. Mizumoto M, Honjo G, Kobashi Y, Nishimura S, Nakamura Y, Yoshimura T, Awane M, Kato Y, Furuyama H, Asao Y, Maeda H, Takakuwa H, Matsusue S: Preoperative evaluation of malignancy in intraductal papillary mucinous neoplasms of the pancreas, especially in relation to dysplastic epithelial changes. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):704-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative evaluation of malignancy in intraductal papillary mucinous neoplasms of the pancreas, especially in relation to dysplastic epithelial changes.
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasms have a better prognosis than ductal adenocarcinomas of the pancreas.
  • The diameters of the tumor, main pancreatic duct and mural nodule were measured on the images.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613438.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Dietrich CF, Jenssen C, Allescher HD, Hocke M, Barreiros AP, Ignee A: [Differential diagnosis of pancreatic lesions using endoscopic ultrasound]. Z Gastroenterol; 2008 Jun;46(6):601-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis of pancreatic lesions using endoscopic ultrasound].
  • The most common pancreatic tumour is the ductal adenocarcinoma.
  • Many other benign and malignant pancreatic neoplasms have to be recognised and now account for more than 50 % of the pancreatic lesions seen in our daily routine.
  • An improved differential diagnosis is, therefore, mandatory and will be discussed in this review.
  • [MeSH-major] Endosonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Biopsy, Fine-Needle. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / ultrasonography. Cell Transformation, Neoplastic / pathology. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / ultrasonography. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / ultrasonography. Cystadenoma, Papillary / pathology. Cystadenoma, Papillary / ultrasonography. Cystadenoma, Serous / pathology. Cystadenoma, Serous / ultrasonography. Diagnosis, Differential. Humans. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / ultrasonography. Pancreas / pathology. Pancreas / ultrasonography. Pancreatic Pseudocyst / pathology. Pancreatic Pseudocyst / ultrasonography. Pancreatitis / pathology. Pancreatitis / ultrasonography. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537088.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 212
  •  go-up   go-down


3. Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C: The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol; 2007 Sep;31(3):567-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.
  • The prognosis of advanced pancreatic cancer is poor.
  • We investigated how far a combination of trichostatin A (TSA) and gemcitabine synergizes to inhibit proliferation and promotion of apoptosis of pancreatic adenocarcinoma cells in vitro.
  • The human pancreatic carcinoma cells YAPC, DANG and Panc-89 and primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with gemcitabine und TSA alone (10(-4) to 10(-8) M) or together (10(-6) to 10(-7) M).
  • Combination of TSA and gemcitabine shows promise for treatment of pancreatic cancer in vivo.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Carcinoma / drug therapy. Cell Proliferation / drug effects. Deoxycytidine / analogs & derivatives. Hydroxamic Acids / administration & dosage. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671683.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 0W860991D6 / Deoxycytidine; 3X2S926L3Z / trichostatin A; B76N6SBZ8R / gemcitabine; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


Advertisement
4. Chang CL, Wu TC, Hung CF: Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther; 2007 Aug;14(16):1189-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma and pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1035-42 [10706121.001]
  • [Cites] Gene Ther. 2007 Jan;14(1):20-9 [16915291.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5492-7 [10779556.001]
  • [Cites] Surgery. 2000 Aug;128(2):273-80 [10923004.001]
  • [Cites] J Leukoc Biol. 2000 Dec;68(6):793-806 [11129646.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):859-63 [11221870.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50 [11553767.001]
  • [Cites] Vaccine. 2001 Nov 12;20(3-4):421-9 [11672905.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):356-60 [11676395.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):41-50 [11836668.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):82-96 [11836673.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3677-84 [11848542.001]
  • [Cites] Gene Ther. 2002 Feb;9(3):208-13 [11859424.001]
  • [Cites] Immunology. 2002 Sep;107(1):39-45 [12225361.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:d55-68 [12456324.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]
  • [Cites] Nat Med. 2003 Jan;9(1):33-9 [12496961.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):600-7 [12566302.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3162-70 [12626574.001]
  • [Cites] Curr Opin Mol Ther. 2003 Feb;5(1):20-4 [12669466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8850-5 [12857959.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):976-83 [14601058.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] IDrugs. 2003 Dec;6(12):1155-64 [14666426.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Nat Med. 2004 Sep;10(9):950-8 [15334073.001]
  • [Cites] Immunity. 1995 Aug;3(2):165-9 [7648389.001]
  • [Cites] Annu Rev Immunol. 1997;15:617-48 [9143702.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3814-20 [15897581.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Vaccine. 2007 Jan 2;25(1):127-35 [16930783.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):89-94 [10728600.001]
  • (PMID = 17581599.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U19 CA113341; United States / NCI NIH HHS / CA / 1U19 CA113341-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Cancer Vaccines; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Vaccines, DNA; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS321551; NLM/ PMC3182456
  •  go-up   go-down


5. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer; 2007 Apr 15;109(8):1561-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
  • BACKGROUND: Erlotinib, in combination with gemcitabine, has shown clinical benefits in pancreatic adenocarcinoma patients.
  • The presence of EGFR mutations and increased EGFR copy numbers in pancreatic adenocarcinoma was explored.
  • METHODS: Sixty-six pancreatic cancer patients were included in the analysis.
  • RESULTS: In the current study the EGFR mutation was harbored in only 1 (1.5%) of the 66 inoperable or metastatic pancreatic adenocarcinoma patients.
  • There was only 1 patient, who had a highly increased EGFR copy number (> or =6.0 per cell), who died, 2.1 months from the date of diagnosis.
  • The EGFR amplification did not significantly influence survival in pancreatic adenocarcinoma patients (P = .935).
  • Thirty-two (49%) of the 65 pancreatic adenocarcinomas examined harbored a point mutation in codons 12 (n = 31) and 61 (n = 1) of the KRAS gene.
  • The presence of a point mutation in codon 12 adversely influenced survival of pancreatic cancer patients (P = .030).
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Pancreatic Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics


6. Fukamachi K, Tanaka H, Hagiwara Y, Ohara H, Joh T, Iigo M, Alexander DB, Xu J, Long N, Takigahira M, Yanagihara K, Hino O, Saito I, Tsuda H: An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas. Biochem Biophys Res Commun; 2009 Dec 18;390(3):636-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas.
  • Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease, which is usually diagnosed in an advanced stage.
  • We believe this is the first report of a pancreas tumor animal model in which pre-symptomatic lesions can be diagnosed.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Pancreatic Ductal / diagnosis. Membrane Glycoproteins / blood. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19818733.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


7. Al-Refaie WB, Choi EA, Tseng JF, Tamm EP, Lee JH, Lee JE, Evans DB, Pisters PW: Intraductal papillary mucinous neoplasms of the pancreas. Med Princ Pract; 2006;15(4):245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas.
  • The introduction of the exocrine pancreatic classification by the World Health Organization and improvements in pancreatic imaging have led to an improved understanding of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
  • As a result, IPMNs of the pancreas are increasingly being recognized as a separate disease entity.
  • IPMNs are characterized by the cystic dilatation of the pancreatic duct and its branches, with papillary projections.
  • The lymph nodes are involved considerably less frequently than they are in pancreatic adenocarcinoma.
  • Most patients are symptomatic at diagnosis and require a diagnostic workup similar to that for patients with pancreatic adenocarcinoma.
  • A mural nodule and a main pancreatic duct diameter greater than 5 mm have been found to be predictors of malignancy.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16763389.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 29
  •  go-up   go-down


8. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A: Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology; 2010;10(1):66-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.
  • BACKGROUND/AIMS: Pancreatic intraepithelial neoplasia (PanIN) is the most common noninvasive precursor to invasive pancreatic adenocarcinoma.
  • METHODS: Three candidate miRNAs (miR-21, miR-155, and miR-221) previously reported as overexpressed in pancreatic cancers were assessed in 31 microdissected PanINs (14 PanIN-1, 9 PanIN-2, 8 PanIN-3) using quantitative reverse transcription PCR (qRT-PCR).
  • CONCLUSIONS: Abnormalities of miRNA expression are observed in the multistep progression of pancreatic cancer, with miR-155 aberrations demonstrable at the stage of PanIN-2, and miR-21 abnormalities at the stage of PanIN-3 lesions. and IAP.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2008 Jan;40(1):43-50 [18066065.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(22):6773-84 [18794355.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] J Mol Diagn. 2008 Mar;10(2):111-22 [18258927.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] PLoS One. 2008;3(7):e2557 [18596939.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] J Gastrointest Surg. 2008 Dec;12(12):2171-6 [18642050.001]
  • [Cites] World J Surg. 2009 Apr;33(4):698-709 [19030927.001]
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):1002-11 [19293812.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] Pancreatology. 2009;9(1-2):66-72 [19077456.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3918-28 [19228262.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Oncology (Williston Park). 2005 Mar;19(3):393-404, 409; discussion 409-10, 412-6 [15828554.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):959-63 [15832197.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1419-23 [17308078.001]
  • [Cites] Leuk Lymphoma. 2007 Feb;48(2):410-2 [17325905.001]
  • [Cites] Mod Pathol. 2007 May;20(5):570-8 [17396143.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):224-32 [17520196.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4442-52 [17237814.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Histopathology. 2007 Oct;51(4):539-46 [17714470.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2007;8:215-39 [17506656.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Cancer Biol Ther. 2007 Aug;6(8):1284-8 [17660710.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]
  • (PMID = 20332664.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50CA062924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MIRN155 microRNA, human; 0 / MIRN21 microRNA, human; 0 / MIRN221 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2865485
  •  go-up   go-down


9. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA: Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest; 2008 Feb;26(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
  • BACKGROUND: No therapeutic standard of care exists for patients with advanced pancreatic cancer who progress following first-line treatment with a gemcitabine-based regimen.
  • There is evidence of synergistic activity between docetaxel and irinotecan, and the combination of these two agents has shown promising efficacy in the first-line setting for advanced pancreatic cancer.
  • METHODS: Eligible patients with metastatic pancreatic adenocarcinoma were required to have an elevated serum CA19-9 (> 2x ULN) and exposure to one or two prior chemotherapy regimens, including one gemcitabine-based.
  • CONCLUSIONS: The combination of docetaxel and irinotecan given on a 21-day cycle is associated with excess toxicity in gemcitabine-refractory patients with advanced pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / toxicity. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181045.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Honda K, Fukuhara T, Kojima Y, Tanaka H, Kushihata F, Kobayashi N: [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2089-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
  • Two cases of advanced pancreas cancer were treated with GTX.
  • A 62-year-old man with pancreas head cancer and 2 liver metastases was treated with GEM 1,000 mg/m(2)/week at weeks 1, 2, and 3, and drug-free week 4 for 3 cycles, but was PD.
  • A 75-year-old man with pancreas head cancer and vascular invasion has been treated with GTX.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy. Vascular Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197760.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Vadalà S, Aronica G, Biondi A, Magnano V, Valastro M, Li Volti G, Cordio S, Giannone G: Distal pancreatectomy with en bloc resection of the celiac axis for pancreatic adenocarcinoma. Clin Ter; 2009;160(4):287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distal pancreatectomy with en bloc resection of the celiac axis for pancreatic adenocarcinoma.
  • Subsequently, Mayumi et al. and Kimura et al. adopted this approach for locally advanced adenocarcinoma of pancreatic body.
  • We are here describing this technique in case of adenocarcinoma of pancreatic body with infiltration of celiac axis achieving also gastric preservation.
  • CT scan showed a 3 cm mass in the body of pancreas infiltrating the origin of celiac axis, causing obstructive atrophy of pancreatic tail.
  • Appleby operation can increase the resectability of locally advanced cancer of the body and tail of the pancreas and offers not only a better life quality for patients but also perfect pain relief.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795078.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


12. Sultana A, Shore S, Raraty MG, Vinjamuri S, Evans JE, Smith CT, Lane S, Chauhan S, Bosonnet L, Garvey C, Sutton R, Neoptolemos JP, Ghaneh P: Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer; 2009 Feb 25;9:66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma.
  • BACKGROUND: Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage.
  • This study aimed to evaluate the safety and tolerability of KAb201, an anti-carcinoembryonic antigen monoclonal antibody, labelled with I(131) in pancreatic cancer (ISRCTN 16857581).
  • METHODS: Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas were randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Carcinoembryonic Antigen / administration & dosage. Immunotoxins / administration & dosage. Iodine Radioisotopes / administration & dosage. Pancreatic Neoplasms / radiotherapy. Radioimmunotherapy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3232s-3242s [10541369.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):406-14 [10690517.001]
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):45-57 [11135320.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6851-9 [11559561.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Cancer. 2002 Feb 15;94(4 Suppl):1373-81 [11877768.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Clin Colorectal Cancer. 2002 May;2(1):31-42 [12453334.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Dec;18(11-12):1049-69 [14653825.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):618-26 [14991585.001]
  • [Cites] J Natl Cancer Inst. 1976 Jul;57(1):11-22 [794493.001]
  • [Cites] Ann N Y Acad Sci. 1983;417:75-85 [6200051.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]
  • [Cites] J Surg Oncol. 1991 Jul;47(3):148-54 [2072697.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):858-70 [9189130.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Nucl Med. 1998 Jan;39(1):34-42 [9443735.001]
  • [Cites] Hepatogastroenterology. 1998 Jul-Aug;45(22):1125-9 [9756018.001]
  • [Cites] Hybridoma. 1999 Apr;18(2):183-91 [10380018.001]
  • [Cites] Surgery. 2005 Jun;137(6):597-605 [15962401.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] Ann Nucl Med. 2005 Jul;19(5):355-65 [16164191.001]
  • [Cites] J Nucl Med. 2006 Feb;47(2):196-9 [16455623.001]
  • [Cites] J Nucl Med. 2006 Feb;47(2):247-55 [16455630.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):823-34 [16380412.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1395-403 [16505413.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3946-52 [16921047.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):248-64 [17043623.001]
  • [Cites] Curr Drug Discov Technol. 2006 Dec;3(4):231-43 [17430101.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2607-15 [17577041.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 19243606.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN16857581
  • [Grant] United Kingdom / Medical Research Council / / G9900432; United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Carcinoembryonic Antigen; 0 / Immunotoxins; 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2656541
  •  go-up   go-down


13. Wong AA, Delclos ME, Wolff RA, Evans DB, Abbruzzese JL, Tamm EP, Xiong HQ, Ho L, Crane CH, Pancreatic Tumor Study Group: Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. Am J Clin Oncol; 2005 Jun;28(3):227-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.
  • Treatment of locally advanced pancreatic cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate.
  • From December 1993 through May 2001, 107 patients with locally advanced adenocarcinoma of the pancreas had been treated with palliative chemoradiation.
  • Compared with higher doses given over 5 to 6 weeks, chemoradiation (30 Gy in 10 fractions in 2 weeks with concurrent infusional 5-FU) results in a similar median survival, and local disease progression rates in patients with locally advanced pancreatic cancer apparently do not substantially improve local disease control or median survival time.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Palliative Care. Pancreatic Neoplasms / radiotherapy. Radiotherapy, High-Energy

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923793.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA06294; United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Kim T, Grobmyer SR, Dixon LR, Hochwald SN: Isolated lymphoplasmacytic sclerosing pancreatitis involving the pancreatic tail. Am Surg; 2008 Jul;74(7):654-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated lymphoplasmacytic sclerosing pancreatitis involving the pancreatic tail.
  • CT imaging revealed a hypodense lesion in the tail of the pancreas.
  • Due to concerns of pancreatic malignancy, she underwent operation.
  • We found a dense, inflammatory mass in the tail of the pancreas, which was removed via an open distal pancreatectomy with splenectomy.
  • Histologic analysis revealed a pancreas with sclerotic ducts and surrounding lymphoplasmacytic inflammation most consistent with lymphoplasmacytic sclerosing pancreatitis (LPSP).
  • LPSP, also termed autoimmune pancreatitis, is a benign disease of the pancreas, which can mimic pancreatic adenocarcinoma.
  • It is the most common benign finding diagnosed on pathology after pancreatic resection for presumed malignancy.
  • LPSP most commonly involves the head and, more uncommonly, the tail of the pancreas.
  • [MeSH-major] Pancreas / pathology. Pancreaticoduodenectomy / methods. Pancreatitis / pathology
  • [MeSH-minor] Chronic Disease. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Sclerosis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646484.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ramani VC, Hennings L, Haun RS: Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer; 2008;8:373
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer.
  • BACKGROUND: In a previous report we have demonstrated that the chymotryptic-like serine protease kallikrein 7 (KLK7/hK7) is overexpressed in pancreatic cancer.
  • Thus, the ability of hK7 to degrade desmogleins was assessed and the effect of hK7 expression on desmoglein 2 was examined in cultured pancreatic cancer cells.
  • METHODS: The expression of Dsg1, Dsg2, and Dsg3 in pancreatic tissues was examined by immunohistochemistry and their expression in two pancreatic cancer cell lines, BxPC-3 and Panc-1, was determined by western blot analysis.
  • RESULTS: The levels of immunoreactive Dsg1 and Dsg2 were reduced in pancreatic adenocarcinomas compared with both normal pancreatic and chronic pancreatitis tissues.
  • CONCLUSION: A reduction in the amount of the cell adhesion components Dsg1 and Dsg2 in pancreatic tumors suggests that loss of these desmosomal proteins may play a role in pancreatic cancer invasion.
  • Using in vitro degradation assays, both Dsg1 and Dsg2 could be readily proteolyzed by hK7, which is overexpressed in pancreatic adenocarcinomas.
  • The enforced expression of hK7 in BxPC-3 cells that express significant amounts of Dsg2 resulted in a marked increase in the shedding of soluble Dsg2, which is consistent with the notion that aberrant expression of hK7 in pancreatic tumors may result in diminished cell-cell adhesion and facilitate tumor cell invasion.
  • [MeSH-major] Adenocarcinoma / metabolism. Desmoglein 2 / metabolism. Kallikreins / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Desmoglein 1 / metabolism. Desmoglein 3 / metabolism. Humans. Immunohistochemistry. Pancreas / metabolism. Pancreas / pathology. Pancreatitis / metabolism. RNA, Messenger / metabolism. Recombinant Proteins / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Nov 15;86(10):2074-82 [10570434.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1235-44 [15140227.001]
  • [Cites] Trends Endocrinol Metab. 2000 Mar;11(2):54-60 [10675891.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):208-16 [11252896.001]
  • [Cites] Pathol Res Pract. 2001;197(2):85-91 [11261822.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):143-52 [11322833.001]
  • [Cites] Biochim Biophys Acta. 2001 Nov 30;1552(1):39-45 [11781114.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61 [11906548.001]
  • [Cites] Exp Dermatol. 2002 Apr;11(2):115-25 [11994138.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Jul;34(3):255-68 [12007186.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1198-205 [12142373.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):237-58 [12784999.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):283-8 [15297163.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1001-6 [15492784.001]
  • [Cites] Br J Urol. 1990 Feb;65(2):176-80 [2317652.001]
  • [Cites] Annu Rev Cell Biol. 1990;6:461-91 [2275820.001]
  • [Cites] Arch Dermatol Res. 1991;283(2):108-12 [1712574.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):353-7 [1729705.001]
  • [Cites] Breast Cancer Res Treat. 1993;24(3):175-84 [8435473.001]
  • [Cites] Semin Cancer Biol. 1993 Aug;4(4):219-29 [8400144.001]
  • [Cites] Semin Cancer Biol. 1993 Aug;4(4):251-8 [8400147.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):204-12 [7540167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Differentiation. 1996 May;60(2):99-108 [8641550.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1491-7 [8664118.001]
  • [Cites] Br J Dermatol. 1996 Mar;134(3):460-4 [8731669.001]
  • [Cites] World J Urol. 1996;14(3):151-6 [8806193.001]
  • [Cites] J Cell Biol. 1997 Jul 14;138(1):193-201 [9214392.001]
  • [Cites] J Cell Sci. 1998 Feb;111 ( Pt 4):495-509 [9443898.001]
  • [Cites] Int Rev Cytol. 1999;185:237-302 [9750269.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 22;329(4):1260-6 [15766562.001]
  • [Cites] J Pathol. 2005 Oct;207(2):199-206 [16025435.001]
  • [Cites] J Invest Dermatol. 2006 Jul;126(7):1622-32 [16628198.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2397-403 [16890424.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):3640-52 [17158887.001]
  • [Cites] Cancer. 2007 May 1;109(9):1811-20 [17354228.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1783-7 [17519903.001]
  • [Cites] Am J Pathol. 2007 Sep;171(3):906-16 [17640963.001]
  • [Cites] Biochem Biophys Res Commun. 2008 May 16;369(4):1169-73 [18343220.001]
  • [Cites] Virchows Arch. 2003 Jul;443(1):51-6 [12759751.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • (PMID = 19091121.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DSG1 protein, human; 0 / DSG2 protein, human; 0 / DSG3 protein, human; 0 / Desmoglein 1; 0 / Desmoglein 2; 0 / Desmoglein 3; 0 / RNA, Messenger; 0 / Recombinant Proteins; EC 3.4.21.- / KLK7 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2628383
  •  go-up   go-down


16. Gulluoglu MG, Karayigit E, Ozden I, Kapran Y, Dizdaroglu F: Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer? Pathology; 2008 Jan;40(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does HepPar-1 immunoexpression have a role in differential diagnosis of periampullary cancer?
  • We assessed the immunoexpression rates of HepPar-1, CDX2 and MUC2 antibodies in different subtypes of periampullary adenocarcinomas (PAC), intestinal and pancreatobiliary, in order to assess their impact on differential diagnosis of this group of cancers.
  • The expression of antibodies was also measured in ductal adenocarcinoma of the pancreatic head (DAPH).
  • METHODS: Sixty-five patients with PAC and DAPH who underwent pancreatic Whipple resection constituted the study cohort.
  • In addition to CDX2 and MUC2 antibodies, HepPar-1 immunoexpression seems to have a potential role in differential diagnosis of PACs.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Antibodies, Monoclonal / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Common Bile Duct Neoplasms / diagnosis. Common Bile Duct Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Common Bile Duct / metabolism. Common Bile Duct / pathology. Diagnosis, Differential. Female. Homeodomain Proteins / immunology. Homeodomain Proteins / metabolism. Humans. Male. Middle Aged. Mucin-2. Mucins / immunology. Mucins / metabolism. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. Retrospective Studies. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038313.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


17. Ricketts R, Tamboli P, Czerniak B, Guo CC: Tumor-to-tumor metastasis: report of 2 cases of metastatic carcinoma to angiomyolipoma of the kidney. Arch Pathol Lab Med; 2008 Jun;132(6):1016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In one case, the donor tumor originated from neuroendocrine carcinoma of the pancreas, and in the other case the donor tumor was from adenocarcinoma of the lung.
  • An awareness of this phenomenon is important to avoid an incorrect diagnosis when encountering unusual morphologic features in renal angiomyolipoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Carcinoma, Neuroendocrine / pathology. Humans. Immunohistochemistry. Lung Neoplasms / pathology. Male. Middle Aged. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18517262.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL: A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs; 2006 Nov;24(6):515-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.
  • PURPOSE: The purpose of this Phase II multi-institutional study was to define the efficacy and toxicity of ixabepilone in patients with advance pancreatic adenocarcinoma.
  • PATIENTS AND METHODS: Patients were required to have pancreatic adenocarcinoma and metastatic or recurrent disease that was not amenable to curative resection.
  • CONCLUSION: Ixabepilone shows encouraging activity in patients with advanced pancreatic cancer and should be investigated further in this disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Epothilones / therapeutic use. Pancreatic Neoplasms / drug therapy. Tubulin Modulators / therapeutic use

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Ixabepilone .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Invest New Drugs. 2005 Oct;23 (5):485-7 [16133800.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2414-9 [9196157.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2610-6 [15226328.001]
  • [Cites] Invest New Drugs. 1994;12(1):29-34 [7960602.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1429-37 [11350914.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1261-8 [10189130.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):101-5 [8554969.001]
  • [Cites] Invest New Drugs. 2006 Nov;24(6):515-20 [16699973.001]
  • (PMID = 16699973.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA27575; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA76429; United States / NCI NIH HHS / CA / CA76447
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epothilones; 0 / Tubulin Modulators; K27005NP0A / ixabepilone
  •  go-up   go-down


19. Søreide K, Immervoll H, Molven A: [Precursors to pancreatic cancer]. Tidsskr Nor Laegeforen; 2006 Mar 23;126(7):905-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Precursors to pancreatic cancer].
  • BACKGROUND: Pancreatic adenocarcinoma is a relatively frequent cancer with an extremely poor prognosis.
  • Until recently, the natural history of pancreatic adenocarcinoma has not been possible to study, but the identification of precursor lesions (pancreatic intraepithelial neoplasia, PanIN) has lead to a better understanding of the stepwise morphological and genetic alterations involved in the development of invasive adenocarcinoma.
  • MATERIAL AND METHODS: Relevant literature from the period of 1996-2005 was found by searching the Medline database, combining the terms "pancreas", "cancer", "PanIN" and "neoplasia".
  • RESULTS AND INTERPRETATION: PanINs are established as designation of histological precursor lesions to pancreatic adenocarcinoma.
  • PanIN grade I to III represent stepwise morphological alterations in the pancreatic ductal epithelium, from early neoplasia (PanIN I and II), via carcinoma in situ (PanIN III) to the development of invasive ductal adenocarcinoma.
  • Increased knowledge about pancreatic carcinogenesis may pave the way for prevention strategies, early detection, and new treatment options, thus ultimately improving the prognosis of the patients.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554881.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 36
  •  go-up   go-down


20. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B: A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist; 2010;15(12):1310-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
  • BACKGROUND: The Cancer and Leukemia Group B (CALGB) conducted a phase II study evaluating sunitinib in patients with progressive metastatic pancreas adenocarcinoma following prior gemcitabine-based therapy (trial CALGB 80603; ClinicalTrials.gov identifier, NCT00397787).
  • PATIENTS AND METHODS: Patients aged ≥18 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 and with progressive pancreas adenocarcinoma following treatment with gemcitabine were eligible.
  • CONCLUSIONS: The study met its primary endpoint; however sunitinib had minimal activity and moderate toxicity in a population of gemcitabine-refractory pancreas adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Indoles / therapeutic use. Pancreatic Neoplasms / drug therapy. Pyrroles / therapeutic use. Salvage Therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):193-8 [19047305.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1439-47 [9849429.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1873-82 [19276273.001]
  • [Cites] Oncology. 2009;76(4):254-61 [19246950.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2231-7 [19307500.001]
  • [Cites] Science. 2009 Jun 12;324(5933):1457-61 [19460966.001]
  • [Cites] Curr Drug Metab. 2009 Jun;10(5):470-81 [19689244.001]
  • [Cites] J Gastrointest Cancer. 2009;40(1-2):1-9 [19513861.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1473-85 [19828009.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1487-97 [19828010.001]
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3617-22 [20606091.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7 [20130876.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:69-73 [10436789.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39 [15648955.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):369-75 [16012797.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):114-20 [17272317.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4787-92 [17947726.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):463-7 [18202421.001]
  • [Cites] BMC Cancer. 2008;8:82 [18373843.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):673-8 [18172650.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2046-52 [18756532.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):159-66; discussion 166 [11992800.001]
  • (PMID = 21148613.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00397787
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / U10 CA086726; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA045389; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / CA86726; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
  • [Other-IDs] NLM/ PMC3227926
  •  go-up   go-down


21. Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M: A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol; 2010 Dec 01;3(6):373-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
  • BACKGROUND: Erlotinib is approved for the treatment of advanced pancreas cancer.
  • We conducted a prospective trial to determine the safety profile and recommended phase 2 dose of erlotinib and capecitabine given concurrently with intensity-modulated radiation therapy (IMRT) in resected pancreatic cancer patients.
  • METHODS: Patients with resected pancreatic adenocarcinoma received erlotinib and capecitabine concurrently with IMRT delivered at 1.8 Gy daily in 28 fractions (total = 50.4 Gy).
  • CONCLUSIONS: When administered concurrently with IMRT, erlotinib 100 mg daily and capecitabine 800 mg/m(2) twice daily (Monday to Friday) can be administered safely in resected pancreas cancer patients, and is the recommended regimen for efficacy studies using this regimen.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151476.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA104900
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3000462
  •  go-up   go-down


22. Ogawa H, Itoh S, Ikeda M, Suzuki K, Naganawa S: Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT. Radiology; 2008 Sep;248(3):876-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT.
  • RESULTS: The following findings showed significant differences among the three groups: maximum diameter of the main pancreatic duct (MPD), size (length of major axis) of the largest mural nodule in the MPD or in any associated cystic lesion, abnormal attenuating area in the surrounding parenchyma, calcification in the lesion, protrusion of the MPD into the ampulla of Vater, and bile duct dilatation.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Adenoma / radiography. Pancreatic Neoplasms / radiography. Papilloma, Intraductal / radiography. Radiographic Image Enhancement / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2008
  • (PMID = 18632526.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Cienfuegos JA, Baixauli J, Zozaya G, Bueno A, Arredondo J, Regueira FM, Angós R, Hernández-Lizoáin JL, Idoate MA: Peutz-Jeghers syndrome and duodeno-jejunal adenocarcinoma--therapeutic implications. Rev Esp Enferm Dig; 2009 Dec;101(12):875-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peutz-Jeghers syndrome and duodeno-jejunal adenocarcinoma--therapeutic implications.
  • Hemminki in 1997 described the presence of LKB-1 mutation tumor-suppressor gen.The patients with PJS develop a higher cumulative incidence of gastrointestinal, pancreas and extraintestinal tumors, being occasion of a renew interest on hamartomatous polyposis syndromes regarding the clinical care, cancer surveillance treatment and long term follow-up.We report the case of a 38 years old male, diagnosed of PJS who developed a multiple adenocarcinoma in duodenum and yeyunum.
  • [MeSH-major] Adenocarcinoma. Duodenal Neoplasms. Jejunal Neoplasms. Neoplasms, Multiple Primary. Peutz-Jeghers Syndrome / complications

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082550.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Kaifi JT, Cataldegirmen G, Wachowiak R, Schurr PG, Kleinhans H, Kosti G, Yekebas EF, Mann O, Kutup A, Kalinin V, Strate T, Izbicki JR: Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis. Anticancer Res; 2007 Jan-Feb;27(1A):69-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short tandem repeat polymorphisms of exon 4 in Kazal-type gene ECRG2 in pancreatic carcinoma and chronic pancreatitis.
  • Kazal-type genes are associated with cancer and pancreatic disease.
  • The aim of the present study was to examine whether ECRG2 STR polymorphisms are associated with pancreatic carcinoma and chronic pancreatitis.
  • MATERIALS AND METHODS: A total of 209 surgically treated patients were analyzed, 92 with pancreatic adenocarcinoma and 117 with chronic pancreatitis.
  • RESULTS: ECRG2 STR of highest incidence was TCA3/TCA3 [47 (51%) in pancreatic carcinoma; 59 (50%) in pancreatitis patients], followed by the TCA3/TCA4 [37 (40%); 54 (46%)] and TCA4/TCA4 [8 (9%); 4 (4%)] genotypes.
  • No correlation in frequency of STRs comparing chronic pancreatitis and pancreatic cancer was determined using the Chi-squared test (p = 0.23).
  • CONCLUSION: The data show that ECRG2 STR polymorphism TCA3/TCA3 in exon 4 is the most prevalent polymorphism found in pancreatic adenocarcinoma and chronic pancreatitis detected in peripheral blood.
  • None of the polymorphisms was associated with poor clinical outcome in pancreatic cancer patients.
  • [MeSH-major] Adenocarcinoma / genetics. Microsatellite Repeats. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352218.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Proteinase Inhibitory Proteins, Secretory; 0 / SPINK7 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


25. Liau SS, Rocha F, Matros E, Redston M, Whang E: High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer; 2008 Jul 15;113(2):302-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma.
  • BACKGROUND: High mobility group AT-hook 1 (HMGA1) proteins are architectural transcription factors that are overexpressed by pancreatic adenocarcinomas.
  • The authors hypothesized that tumor HMGA1 status represents a novel prognostic marker in pancreatic adenocarcinoma.
  • METHODS: Tumor HMGA1 expression was examined by immunohistochemical analysis of tissues from 89 consecutive patients who underwent resection for pancreatic adenocarcinoma.
  • Short-hairpin RNA (shRNA)-mediated RNA interference was used to silence HMGA1 expression in MiaPaCa2 and PANC1 pancreatic cancer cells.
  • RESULTS: Tumor HMGA1 expression was detected in 93% of patients with pancreatic adenocarcinoma.
  • CONCLUSIONS: The current findings suggested that HMGA1 is an independent predictor of poor postoperative survival in patients with pancreatic adenocarcinoma.
  • HMGA1 warrants further evaluation as a prognostic marker and therapeutic target in pancreatic cancer.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1990 May 25;265(15):8573-82 [1692833.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):993-1000 [17342093.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):619-26 [8106557.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1786-96 [7862168.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1091-100 [8548797.001]
  • [Cites] Oncogene. 1997 Jun 19;14(24):2971-7 [9205104.001]
  • [Cites] Oncogene. 1998 May;16(20):2681-6 [9632144.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7637-44 [15569996.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3117-22 [10866296.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(2):575-94 [11134344.001]
  • [Cites] Pancreas. 2002 Jan;24(1):42-6 [11741181.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):777-85 [14737112.001]
  • [Cites] Langenbecks Arch Surg. 2004 Jun;389(3):193-7 [15107999.001]
  • [Cites] Nature. 2004 Aug 26;430(7003):1034-9 [15329723.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6543-6 [2819710.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 30;335(3):949-56 [16105664.001]
  • [Cites] Dig Dis Sci. 2005 Oct;50(10):1764-70 [16187170.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2980-9 [16540646.001]
  • [Cites] J Pathol. 2006 Jun;209(2):206-12 [16521118.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2470-8 [16936195.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1254-62; discussion 1263 [17114012.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11613-22 [17178855.001]
  • [Cites] Exp Cell Res. 2007 Jan 1;313(1):77-87 [17045586.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):693-702 [17290307.001]
  • [Cites] Nucleic Acids Res. 1993 Sep 11;21(18):4259-67 [8414980.001]
  • (PMID = 18473350.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114103-04; United States / NCI NIH HHS / CA / R01 CA114103; United States / NCI NIH HHS / CA / R01 CA114103-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 124544-67-8 / HMGA1a Protein; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  • [Other-IDs] NLM/ NIHMS253257; NLM/ PMC2997611
  •  go-up   go-down


26. Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, Büchler MW, Friess H: The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg; 2006 Aug;244(2):274-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The neurotrophic factor artemin promotes pancreatic cancer invasion.
  • OBJECTIVE: To analyze the role of Artemin in pancreatic ductal adenocarcinoma (PDAC) in terms of expression, influence on cancer cell behavior, and pain correlation.
  • METHODS: Artemin and its receptors (GFRalpha3/RET) were studied in PDAC tissues and normal pancreas by Western blot analysis and immunohistochemistry.
  • RNA expression was analyzed in pancreatic tissues (normal, cancer) and pancreatic cancer cell lines by QRT-PCR.
  • RESULTS: Artemin and GFRalpha3/RET were both detected at enhanced levels in PDAC compared with normal pancreas, localizing predominantly in hypertrophic nerves and arterial walls, as well as in cancer cells of primary and metastatic lesions.
  • However, Artemin promoted pancreatic cancer cell invasion up to 5-fold, without affecting cancer cell proliferation.
  • However by increasing cancer cell invasion, Artemin seems to influence neural invasion and thereby contribute to cancer cell spreading along pancreatic nerves.
  • [MeSH-major] Adenocarcinoma / pathology. Nerve Growth Factors / physiology. Nerve Tissue Proteins / physiology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Proliferation. Coloring Agents. Glial Cell Line-Derived Neurotrophic Factor Receptors / physiology. Humans. Hypertrophy. Immunohistochemistry. Neoplasm Invasiveness. Nerve Regeneration / physiology. Neurons / pathology. Pain / physiopathology. Pancreas / innervation. Pancreas / pathology. Polymerase Chain Reaction. Prospective Studies. Tetrazolium Salts. Thiazoles

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2003 Aug;27(2):190-6 [12883269.001]
  • [Cites] Ann Surg. 2005 Jan;241(1):144-51 [15622002.001]
  • [Cites] Nat Med. 2003 Nov;9(11):1383-9 [14528299.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):71-81 [14712212.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5291-300 [15289335.001]
  • [Cites] Cancer. 1987 Nov 1;60(9):2284-303 [3326653.001]
  • [Cites] Ann Surg. 1989 Feb;209(2):181-7 [2464969.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):529-36 [1985049.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Science. 1993 May 21;260(5111):1130-2 [8493557.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):219-30 [8020665.001]
  • [Cites] Nature. 1996 Dec 5;384(6608):467-70 [8945474.001]
  • [Cites] J Biol Chem. 1998 Feb 6;273(6):3502-8 [9452475.001]
  • [Cites] J Neurosci. 1999 Nov 1;19(21):9322-31 [10531437.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3412-20 [10652334.001]
  • [Cites] Development. 2000 Oct;127(20):4335-44 [11003834.001]
  • [Cites] Pancreas. 2001 Apr;22(3):279-84 [11291930.001]
  • [Cites] Eur J Neurosci. 2001 Jun;13(11):2177-82 [11422460.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):361-73 [11544105.001]
  • [Cites] Development. 2001 Oct;128(19):3685-95 [11585795.001]
  • [Cites] Development. 2001 Oct;128(20):3963-74 [11641220.001]
  • [Cites] Pancreas. 2002 Jan;24(1):15-25 [11741178.001]
  • [Cites] J Biol Chem. 2002 Jan 18;277(3):1991-9 [11713247.001]
  • [Cites] Neuron. 2002 Jul 18;35(2):267-82 [12160745.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Nat Med. 2003 May;9(5):589-95 [12669033.001]
  • [Cites] Neuron. 1998 Feb;20(2):245-53 [9491986.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5801-6 [9576965.001]
  • [Cites] J Am Coll Surg. 1998 Jun;186(6):675-82 [9632157.001]
  • [Cites] J Neurol. 1998 Nov;245(11 Suppl 3):P35-42 [9808338.001]
  • [Cites] Neuron. 1998 Dec;21(6):1291-302 [9883723.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):67-73 [10077155.001]
  • [Cites] Surgery. 2003 Aug;134(2):293-9 [12947332.001]
  • (PMID = 16858191.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARTN protein, human; 0 / Coloring Agents; 0 / Glial Cell Line-Derived Neurotrophic Factor Receptors; 0 / Nerve Growth Factors; 0 / Nerve Tissue Proteins; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue
  • [Other-IDs] NLM/ PMC1602177
  •  go-up   go-down


27. Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA, Frame MC, Evans TR, Sansom OJ, Brunton VG: Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology; 2010 Jul;139(1):292-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.
  • BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a highly invasive and metastatic disease for which conventional treatments are of limited efficacy.
  • Targeting expression of Trp53(R172H) and Kras(G12D) to the mouse pancreas results in the formation of invasive and metastatic PDAC.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / drug therapy. Pancreatic Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Thiazoles / therapeutic use. src-Family Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20303350.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United Kingdom / Chief Scientist Office / / CAF/06/24; United Kingdom / Cancer Research UK / / C157/A9148; United Kingdom / Chief Scientist Office / / ; United Kingdom / Cancer Research UK / / C2193/A7603
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.2 / src-Family Kinases; RBZ1571X5H / Dasatinib
  •  go-up   go-down


28. Nuernberg D, Ignee A, Dietrich CF: [Ultrasound in gastroenterology. Biliopancreatic system]. Med Klin (Munich); 2007 Feb 15;102(2):112-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GALLBLADDER: Ultrasound has become widely accepted for the diagnosis of gallbladder disease.
  • PANCREAS: In diagnostic imaging of the pancreas ultrasound stands at the beginning of a diagnostic cascade.
  • Ductal adenocarcinoma seems to be less vascularized in comparison to the surrounding tissue, while endocrine tumors and macro- and microcystic adenoma are rather hypervascularized.
  • [MeSH-major] Biliary Tract Diseases / ultrasonography. Pancreatic Diseases / ultrasonography
  • [MeSH-minor] Adenoma / ultrasonography. Bile Duct Neoplasms / ultrasonography. Bile Ducts, Intrahepatic / ultrasonography. Carcinoma / ultrasonography. Cholangiocarcinoma / ultrasonography. Cholangitis, Sclerosing / ultrasonography. Cholecystitis / ultrasonography. Choledocholithiasis / ultrasonography. Contrast Media. Diagnosis, Differential. Endosonography. Gallbladder Neoplasms / ultrasonography. Humans. Middle Aged. Pancreatic Neoplasms / ultrasonography. Pancreatitis / ultrasonography. Polyps / ultrasonography. Sensitivity and Specificity. Ultrasonography, Doppler, Color / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17323018.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 228
  •  go-up   go-down


29. Sceusi EL, Wray CJ: Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence. World J Surg Oncol; 2009;7:98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma in a patient with situs inversus: a case report of this rare coincidence.
  • BACKGROUND: Situs inversus (SI) is a relatively rare occurrence in patients with pancreatic adenocarcinoma.
  • Pancreatic resection in these patients has rarely been described.
  • CT scan imaging is a principle modality for detecting pancreatic cancer and its use in SI patients is seldom reported.
  • CASE PRESENTATION: We report a 48 year old woman with SI who, despite normal CT scan 8 months earlier, presented with obstructive jaundice and a pancreatic head mass requiring a pancreaticoduodenectomy.
  • The surgical pathology report demonstrated pancreatic adenocarcinoma.
  • CONCLUSION: SI is a rare condition with concurrent pancreatic cancer being even rarer.
  • Additionally, radiographic imaging has significantly improved detection of early pancreatic cancer; however, there continues to be a need for improved detection of small neoplasms.
  • [MeSH-major] Adenocarcinoma / complications. Pancreatic Neoplasms / complications. Situs Inversus / complications

  • Genetic Alliance. consumer health - Situs inversus.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2009 Oct;19(10):2448-55 [19415290.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Dec;6(12):1301-8 [18948228.001]
  • [Cites] Transplant Proc. 2008 Jun;40(5):1792-5 [18589199.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):524-7 [17081721.001]
  • [Cites] Wiad Lek. 2006;59(9-10):707-9 [17338134.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Sep;22(5):512-9 [16891882.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Semin Cell Dev Biol. 1998 Feb;9(1):89-99 [9572118.001]
  • [Cites] J Clin Gastroenterol. 1997 Mar;24(2):92-6 [9077725.001]
  • [Cites] AJR Am J Roentgenol. 2004 Apr;182(4):897-903 [15039161.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):606-7 [12781900.001]
  • [Cites] Radiol Clin North Am. 2002 Dec;40(6):1263-72 [12479710.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] Am J Med Genet. 2001 Jul 15;101(4):345-55 [11471158.001]
  • [Cites] Surg Radiol Anat. 2000;22(5-6):293-7 [11236325.001]
  • [Cites] Radiographics. 2002 Nov-Dec;22(6):1439-56 [12432114.001]
  • (PMID = 20021643.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803176
  •  go-up   go-down


30. Chang SM, Yan ST, Wei CK, Lin CW, Tseng CE: Solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreas. World J Gastroenterol; 2010 Jun 7;16(21):2692-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary concomitant endocrine tumor and ductal adenocarcinoma of pancreas.
  • Pancreatic tumors with combined exocrine and endocrine features are rare.
  • Most reported cases are classified as mixed exocrine and endocrine carcinoma of the pancreas.
  • We report the first case of solitary concomitant endocrine tumor and ductal adenocarcinoma of the pancreas.
  • The tumor was fortuitously discovered in the pancreatic tail after a tumor survey panel.
  • The exocrine part showed a poorly-differentiated adenocarcinoma.
  • We reviewed the literature on pancreatic tumors with combined exocrine and endocrine features.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Endocrine Gland Neoplasms / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West J Med. 1986 Jun;144(6):746-9 [3014756.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1766-70 [6089999.001]
  • [Cites] J Gastroenterol. 1997 Aug;32(4):562-5 [9250909.001]
  • [Cites] Int J Pancreatol. 1999 Apr;25(2):77-87 [10360219.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):231-5 [15517367.001]
  • [Cites] Pancreas. 2005 Jul;31(1):79-83 [15968252.001]
  • [Cites] JOP. 2005 Sep;6(5):449-54 [16186667.001]
  • [Cites] Pancreatology. 2006;6(6):520-6 [17124434.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):981-7 [18395079.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):284-6 [10656740.001]
  • [Cites] Int J Pancreatol. 2000 Jun;27(3):249-57 [10952408.001]
  • [Cites] Surg Today. 2001;31(2):177-9 [11291717.001]
  • [Cites] Histopathology. 2002 Aug;41(2):122-6 [12147089.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):473-5 [15313692.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):263-71 [7076209.001]
  • [Cites] J Korean Med Sci. 1996 Apr;11(2):188-92 [8835769.001]
  • (PMID = 20518094.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Hypoglycemic Agents; 0 / Synaptophysin; 9007-92-5 / Glucagon
  • [Other-IDs] NLM/ PMC2880785
  •  go-up   go-down


31. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


32. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E: Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma; 2009;56(1):56-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma.
  • The aim of our study was to assess the clinical significance of -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms as well as TNF-alpha and INF-gamma serum levels in pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP) as regards to healthy volunteers.
  • We studied 41 patients with pancreatic adenocarcinoma, 56 with chronic pancreatitis and 50 healthy volunteers.
  • -308G/A TNF-alpha and +874A/T INF-gamma genes polymorphisms probably do not play important role in pancreatic diseases.
  • Key words: pancreatic adenocarcinoma, tumor necrosis factor alpha, interferon gamma, cytokines, polymorphism.
  • [MeSH-major] Adenocarcinoma / genetics. Interferon-gamma / genetics. Pancreatic Neoplasms / genetics. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152246.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


33. Mané JM, Sancho A, Muñoz A, Rubio I, Fernández R, Carrera S, Fuente N, Ballesteros D, Casas R, Marrodán I, Mielgo X, López-Vivanco G: Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma. Tumori; 2010 May-Jun;96(3):405-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma.
  • AIMS AND BACKGROUND: Gemcitabine is an effective agent in pancreatic adenocarcinoma.
  • We conducted a trial to confirm efficacy and toxicity of fixed-dose-rate gemcitabine in patients with pancreatic or biliary tree adenocarcinoma.
  • METHODS: Eligible patients with locally advanced or metastatic pancreatic or biliary tree adenocarcinoma received fixed-dose-rate gemcitabine at a dose of 1500 mg/m(2) at a rate of 10 mg/m(2)/min weekly for 3 weeks every 28 days.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Biliary Tract Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845800.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


34. Lang ZQ, Qu GM, Yao WD, Jiang L: Microadenocarcinoma in the head of the pancreas. Chin Med J (Engl); 2007 Oct 20;120(20):1853-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microadenocarcinoma in the head of the pancreas.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Neuroendocrine / diagnosis. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028787.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


35. Keleg S, Kayed H, Jiang X, Penzel R, Giese T, Büchler MW, Friess H, Kleeff J: Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer; 2007 Jul 1;121(1):21-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion.
  • In this study, the expression and functional role of ADM and its signaling components were investigated in pancreatic adenocarcinoma (PDAC).
  • By QRT-PCR, median mRNA levels of ADM and CRLR were 1.5- and 2.4-fold higher, respectively, in PDAC tissues compared to normal pancreatic tissues.
  • By immunohistochemistry, ADM, CRLR, RAMP1 and RAMP2, but not RAMP3, were expressed in pancreatic cancer cells.
  • All 5 evaluated pancreatic cancer cells lines expressed ADM, CRLR, RAMP1 and RAMP2, whereas RAMP3 was expressed in only 1/5 pancreatic cancer cell lines.
  • ADM was strongly induced by hypoxia and significantly increased invasiveness in 3/5 human pancreatic cancer cells.
  • Blocking of CRLR decreased invasiveness in 4/5 human pancreatic cancer cells.
  • Furthermore, ADM increases invasiveness of some pancreatic cancer cells and might influence angiogenesis, suggesting that blocking this pathway might have a therapeutic potential.
  • [MeSH-major] Adrenomedullin / metabolism. Cell Hypoxia. Cell Movement. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Calcitonin Receptor-Like Protein. Cell Line. Cell Proliferation. Gene Expression Regulation, Neoplastic. Humans. Intracellular Signaling Peptides and Proteins / genetics. Membrane Proteins / genetics. Middle Aged. Neoplasm Invasiveness / pathology. Pancreas / metabolism. RNA, Messenger / genetics. Receptor Activity-Modifying Protein 1. Receptor Activity-Modifying Protein 2. Receptor Activity-Modifying Protein 3. Receptor Activity-Modifying Proteins. Receptors, Calcitonin / genetics. Signal Transduction. Transforming Growth Factor beta1 / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290391.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CALCRL protein, human; 0 / Calcitonin Receptor-Like Protein; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RAMP1 protein, human; 0 / RAMP2 protein, human; 0 / RAMP3 protein, human; 0 / RNA, Messenger; 0 / Receptor Activity-Modifying Protein 1; 0 / Receptor Activity-Modifying Protein 2; 0 / Receptor Activity-Modifying Protein 3; 0 / Receptor Activity-Modifying Proteins; 0 / Receptors, Calcitonin; 0 / Transforming Growth Factor beta1; 0 / Vascular Endothelial Growth Factor A; 148498-78-6 / Adrenomedullin
  •  go-up   go-down


36. Balci NC, Perman WH, Saglam S, Akisik F, Fattahi R, Bilgin M: Diffusion-weighted magnetic resonance imaging of the pancreas. Top Magn Reson Imaging; 2009 Feb;20(1):43-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted magnetic resonance imaging of the pancreas.
  • The technique is more frequently used in body imaging, and recent investigations showed its use in pancreatic imaging.
  • Diffusion-weighted imaging can be helpful as a complementary imaging method in the differentiation between mass-forming focal pancreatitis and pancreatic adenocarcinoma.
  • The apparent diffusion coefficient (ADC) values derived from DWI can distinguish between simple pancreatic cyst, inflammatory cysts, and cystic neoplasms of the pancreas.
  • In this paper, we reviewed the technical aspects of DWI and its use in pancreatic imaging.
  • [MeSH-major] Cholangiopancreatography, Magnetic Resonance / methods. Cholangiopancreatography, Magnetic Resonance / trends. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Pancreas / pathology. Pancreatic Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687725.001).
  • [ISSN] 1536-1004
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


37. Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, Tanaka A: Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathol Int; 2005 Feb;55(2):63-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas.
  • The expression of claudin-4 was investigated in human pancreas, pancreatic ductal adenocarcinomas, and intraductal papillary-mucinous tumors of the pancreas (IPMT), and compared with that of claudin-1.
  • In human adult pancreatic specimens, both claudin-1 and claudin-4 were immunohistochemically found in main and branching pancreatic ducts, terminal ductules and acinic cells, with the exception of endocrine cells.
  • Of 12 cases of pancreatic ductal adenocarcinoma, 11 (92%) had positive immunostaining for claudin-4, and seven (58%) for claudin-1.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Papillary / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Membrane Proteins / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Claudin-1. Claudin-4. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Pancreas / metabolism. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693851.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


38. Hruban RH, Maitra A, Goggins M: Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol; 2008;1(4):306-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on pancreatic intraepithelial neoplasia.
  • Pancreatic intraepithelial neoplasia (PanIN) is a histologically well-defined precursor to invasive ductal adenocarcinoma of the pancreas.
  • Molecular studies have helped establish the progression of PanIN to invasive cancer, and recently genetically engineered mouse models have been generated that recapitulate the entire spectrum of lesions from precursor to invasive pancreatic cancer.
  • Some PanIN lesions produce lobulocentric atrophy of the pancreatic parenchyma, and, when multifocal, this lobulocentric atrophy may be detectable using currently available imaging techniques such as endoscopic ultrasound.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2005 Sep;8(3):185-95 [16169464.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):141-7 [15782177.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1495-501 [14657708.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):996-1006 [14559982.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):622-5 [12697855.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 [12673124.001]
  • [Cites] Pancreas. 2003 Apr;26(3):e48-54 [12657964.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):293-6 [12432281.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1541-7 [12414502.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):194-201 [12162677.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1573-81 [12000709.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):635-43 [11756558.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2005-9 [12727809.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] JAMA. 2000 Oct 18;284(15):1954-61 [11035892.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):83-92 [10880379.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1767-71 [10793087.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1835-9 [10766168.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):17-23 [15720814.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1703-10 [10223563.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Ann Diagn Pathol. 1998 Oct;2(5):286-92 [9845751.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4740-4 [9788631.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):515-21 [9641496.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):163-9 [9500216.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2140-3 [9187111.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):227-31 [8536861.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3568-73 [8012983.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):953-6 [8439969.001]
  • [Cites] Cancer. 1979 Apr;43(4):1418-28 [445339.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1674-80 [15188160.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Mol Imaging. 2007 Mar-Apr;6(2):131-9 [17445507.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7068-71 [17652141.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):263-73 [17591971.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):645-6 [17414117.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4437-42 [17360542.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):291-302 [17349585.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):211-3 [17349578.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1844-55 [17087933.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5417-22 [17000675.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5411-6 [17000674.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):286-95 [16858539.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):754-9 [16723855.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):242-7 [16397237.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):95-106 [16397221.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1784-92 [16251534.001]
  • (PMID = 18787611.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480542
  • [Keywords] NOTNLM ; Pancreatic cancer / epigenetics / genetics / intraepithelial neoplasm / metaplasia
  •  go-up   go-down


39. Kurisu Y, Shibayama Y, Tsuji M, Kurokawa A, Akutagawa H, Egashira Y, Matsuo T, Itabashi T: A case of primary ductal adenocarcinoma of the lacrimal gland: histopathological and immunohistochemical study. Pathol Res Pract; 2005;201(1):49-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary ductal adenocarcinoma of the lacrimal gland: histopathological and immunohistochemical study.
  • We encountered primary ductal adenocarcinoma of the lacrimal gland in a 67-year-old Japanese man.
  • To the best of our knowledge, only three cases of primary ductal adenocarcinoma of the lacrimal gland have been reported in the literature.
  • The mass was resected, and primary ductal adenocarcinoma of the lacrimal gland was diagnosed histopathologically.
  • He died from recurrence at the primary site and metastasis to the brain, lungs, liver, common bile duct, and pancreas 2 years and 10 months after surgery although adjunctive orbital radiotherapy was given.
  • It was not clear whether the ductal adenocarcinoma originated from the ductal or acinar epithelium of the lacrimal gland, because the immunohistochemical features of both epithelia were identical.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807311.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 14
  •  go-up   go-down


40. Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC: Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med; 2009 Dec 11;7:105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.
  • BACKGROUND: Pancreatic cancer continues to prove difficult to clinically diagnose.
  • Multiple simultaneous measurements of plasma biomarkers can increase sensitivity and selectivity of diagnosis.
  • METHODS: We examined the plasma levels of 21 biomarkers in a clinically defined cohort of 52 locally advanced (Stage II/III) pancreatic ductal adenocarcinoma cases and 43 age-matched controls using a multiplex proximity ligation assay.
  • The optimal biomarker panel for diagnosis was computed using a combination of the PAM algorithm and logistic regression modeling.
  • RESULTS: Three markers, CA19-9, OPN and CHI3L1, measured in multiplex were found to have superior sensitivity for pancreatic cancer vs. CA19-9 alone (93% vs. 80%).
  • In addition, we identified two markers, CEA and CA125, that when measured simultaneously have prognostic significance for survival for this clinical stage of pancreatic cancer (p < 0.003).
  • CONCLUSIONS: A multiplex panel assaying CA19-9, OPN and CHI3L1 in plasma improves accuracy of pancreatic cancer diagnosis.
  • A panel assaying CEA and CA125 in plasma can predict survival for this clinical cohort of pancreatic cancer patients.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5291-7 [17114663.001]
  • [Cites] Cancer Biomark. 2005;1(6):259-69 [17192050.001]
  • [Cites] Expert Opin Ther Targets. 2007 Feb;11(2):219-34 [17227236.001]
  • [Cites] Nat Methods. 2007 Apr;4(4):327-9 [17369836.001]
  • [Cites] Clin Chem. 2008 Mar;54(3):582-9 [18171715.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Metastasis Rev. 2008 Sep;27(3):351-62 [18483785.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81 [18843033.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4771-6 [18779603.001]
  • [Cites] Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):333-45 [18952487.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):572-8 [19075264.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):473-7 [11981560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Oncogene. 2009 Sep 24;28(38):3412-22 [19597469.001]
  • [Cites] BMC Cancer. 2009;9:8 [19134206.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):59-67 [12538452.001]
  • [Cites] Acta Obstet Gynecol Scand. 2003 Mar;82(3):287-93 [12694127.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(1):15-21 [12889595.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8420-4 [15155907.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5489-92 [6193872.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2287-90 [3179943.001]
  • [Cites] Pancreas. 1994 Nov;9(6):735-40 [7846017.001]
  • [Cites] Eur J Cancer. 1995;31A(9):1437-42 [7577068.001]
  • [Cites] Clin Chem. 1997 Sep;43(9):1749-56 [9299971.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1494-9 [10188896.001]
  • [Cites] Eur J Surg Oncol. 2005 Mar;31(2):164-9 [15698733.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18 [15734951.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4524-31 [16002843.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • (PMID = 20003342.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA67166
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2796647
  •  go-up   go-down


41. Yeh TS, Tseng JH, Chiu CT, Liu NJ, Chen TC, Jan YY, Chen MF: Cholangiographic spectrum of intraductal papillary mucinous neoplasm of the bile ducts. Ann Surg; 2006 Aug;244(2):248-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Bile Duct Neoplasms / classification. Bile Ducts, Intrahepatic / radiography. Cholangiography / methods. Precancerous Conditions / classification

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2005 Apr;30(3):233-8 [15782100.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1206-9 [9752860.001]
  • [Cites] Hepatology. 2000 Jan;31(1):12-7 [10613721.001]
  • [Cites] Dig Dis Sci. 2000 Feb;45(2):312-6 [10711444.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):166-74 [10903592.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):721-5 [10954456.001]
  • [Cites] AJR Am J Roentgenol. 2000 Oct;175(4):1135-9 [11000178.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):651-8 [11584359.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] Br J Surg. 2004 Jan;91(1):99-104 [14716802.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):53-66; discussion 66-7 [14730036.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):327-38 [15104295.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2461-5 [8384069.001]
  • [Cites] Surgery. 1996 Sep;120(3):509-14 [8784405.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):63-9 [9445112.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]
  • (PMID = 16858187.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1602176
  •  go-up   go-down


42. Freitas D, Fernandes Gdos S, Hoff PM, Cunha JE: Medical management of pancreatic adenocarcinoma. Pancreatology; 2009;9(3):223-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of pancreatic adenocarcinoma.
  • Pancreatic cancer is the fourth leading cause of cancer death in the United States.
  • In 2008, an estimated 34,290 people died from pancreatic cancer and 37,680 new cases were diagnosed.
  • Despite modern treatment, 90% of patients die within 1 year of diagnosis.
  • In the present paper the English-language literature addressing the medical management in pancreatic cancer was reviewed.
  • Based on these data we will discuss the role of currently used chemotherapy and target therapy in pancreatic cancer, as well as perspectives of the emerging strategies that are arising in order to improve the outcomes of this complex disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19420981.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  • [Number-of-references] 112
  •  go-up   go-down


43. Ionescu M, Dumitraşcu T, Stroescu C, Ciurea S, Popescu I: [Resection of the celiac axis increase resectability rate in locally advanced pancreatic body and gastric tumor]. Chirurgia (Bucur); 2006 May-Jun;101(3):297-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resection of the celiac axis increase resectability rate in locally advanced pancreatic body and gastric tumor].
  • [Transliterated title] Rezectia de trunchi celiac--factor de creştere a rezecabilităţii in neoplasmele pancreatice si gastrice local avansate.
  • Carcinoma of the body and tail of the pancreas is often diagnosed at an advanced stage or metastatic stage.
  • [MeSH-major] Adenocarcinoma / surgery. Celiac Artery / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927919.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


44. Donadelli M, Dalla Pozza E, Costanzo C, Scupoli MT, Scarpa A, Palmieri M: Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes. J Cell Biochem; 2008 May 1;104(1):202-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes.
  • We investigated the ability of the zinc chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) to reduce pancreatic cancer cell viability.
  • TPEN was much more efficient to inhibit pancreatic adenocarcinoma cell growth than a panel of anti-cancer drugs, including 5-fluorouracil, irinotecan, cisplatin, edelfosine, trichostatin A, mitomycin C, and gemcitabine, the gold standard chemotherapeutic agent for pancreatic cancer.
  • Moreover, TPEN showed a dose- and time-dependent anti-proliferative effect significantly higher on pancreatic cancer cells than on normal primary fibroblasts.
  • This effect may be explained by a significantly higher zinc depletion by TPEN in pancreatic cancer cells as compared to fibroblasts.
  • In this study, we suggest that zinc depletion may be an efficient strategy in the treatment of pancreatic cancer because of its reduced antiproliferative effect on normal cells.
  • [MeSH-major] Cell Proliferation / drug effects. Ethylenediamines / pharmacology. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / therapy. Zinc / deficiency

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979179.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Ethylenediamines; 16858-02-9 / N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; J41CSQ7QDS / Zinc
  •  go-up   go-down


45. Benedix F, Lippert H, Meyer F: [Acute inguinal swelling--unusual presentation of postoperative necrotising pancreatitis]. Zentralbl Chir; 2009 Apr;134(2):186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a 61-year-old male who underwent explorative laparotomy for pancreatic tumour.
  • Intraoperatively, the diagnosis of a locally advanced carcinoma of the head of the pancreas was confirmed histologically.
  • [MeSH-major] Adenocarcinoma / surgery. Edema / surgery. Inguinal Canal / surgery. Pancreatic Neoplasms / surgery. Pancreatitis, Acute Necrotizing / surgery. Postoperative Complications / surgery
  • [MeSH-minor] Abdominal Abscess / diagnosis. Abdominal Abscess / pathology. Abdominal Abscess / surgery. Diagnosis, Differential. Hernia, Inguinal / diagnosis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Reoperation


46. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol; 2010 Aug 01;28(22):3605-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
  • PURPOSE: Patients with advanced pancreas cancer present with disease that is poorly responsive to conventional therapies.
  • Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in patients with pancreas cancer.
  • PATIENTS AND METHODS: Patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma were randomly assigned to receive gemcitabine alone or gemcitabine plus cetuximab.
  • CONCLUSION: In patients with advanced pancreas cancer, the anti-EGFR monoclonal antibody cetuximab did not improve the outcome compared with patients treated with gemcitabine alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2926-35 [10850439.001]
  • [Cites] Cancer. 2000 Jul 1;89(1):74-82 [10897003.001]
  • [Cites] Cancer Invest. 2003;21(1):73-86 [12643012.001]
  • [Cites] Pancreas. 2004 Jul;29(1):e1-8 [15211117.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2610-6 [15226328.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Anticancer Res. 1993 May-Jun;13(3):565-9 [8317885.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):676-85 [16847885.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):39-44 [18077217.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):7-8 [18177814.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell Mol Life Sci. 2008 May;65(10):1566-84 [18259690.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):1-5 [18506149.001]
  • [CommentIn] J Clin Oncol. 2011 Jan 20;29(3):e70-1; author reply e72-3 [21149660.001]
  • (PMID = 20606093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00075686
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / U10 CA035128; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA035192; United States / NCI NIH HHS / CA / U10 CA077202; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA045461; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / U10 CA091105; United States / NCI NIH HHS / CA / U10 CA045450; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / U10 CA035262; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / U10 CA095860; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA067663; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / U10 CA058861; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ PMC2917315
  •  go-up   go-down


47. Fukukura Y, Hamada H, Kamiyama T, Yoneyama T, Takumi K, Nakajo M: Pancreatic adenocarcinoma: analysis of the effect of various concentrations of contrast material. Radiat Med; 2008 Jul;26(6):355-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma: analysis of the effect of various concentrations of contrast material.
  • PURPOSE: The aim of this study was to compare the efficacy of two contrast materials with moderate and high iodine concentrations for the depiction of pancreatic adenocarcinoma.
  • MATERIALS AND METHODS: A series of 107 patients with histologically proven pancreatic adenocarcinoma underwent helical computed tomography.
  • We evaluated enhancement of the aorta, portal vein, hepatic parenchyma, pancreatic parenchyma, and pancreatic adenocarcinoma during each phase.
  • RESULTS: During all phases, both aortic and pancreatic enhancement were significantly greater in group B than in group A (P<0.01).
  • Tumor-to-pancreas contrast was significantly greater in group B than in group A at both 30 s (P<0.01) and 70 s (P<0.05).
  • CONCLUSION: Administration of contrast material with a high iodine concentration is more effective for depicting pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Contrast Media / administration & dosage. Iopamidol / administration & dosage. Pancreatic Neoplasms / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] Radiat Med. 2003 Mar-Apr;21(2):74-9 [12816354.001]
  • [Cites] AJR Am J Roentgenol. 1994 Jun;162(6):1425-9 [8192012.001]
  • [Cites] AJR Am J Roentgenol. 2006 Feb;186(2):406-15 [16423946.001]
  • [Cites] Radiology. 1995 Oct;197(1):89-93 [7568860.001]
  • [Cites] Radiology. 1999 Jan;210(1):97-101 [9885593.001]
  • [Cites] Radiology. 1995 Apr;195(1):1-8 [7892446.001]
  • [Cites] Radiology. 1992 May;183(2):297-303 [1561324.001]
  • [Cites] AJR Am J Roentgenol. 2006 Feb;186(2):379-85 [16423942.001]
  • [Cites] Radiology. 1999 Aug;212(2):445-52 [10429702.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jul;167(1):49-55 [8659419.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1671-7 [8635074.001]
  • [Cites] AJR Am J Roentgenol. 2002 Apr;178(4):821-6 [11906855.001]
  • [Cites] Radiology. 1998 Feb;206(2):373-8 [9457188.001]
  • [Cites] Radiology. 2000 Sep;216(3):718-23 [10966700.001]
  • [Cites] Radiology. 1998 Feb;206(2):455-64 [9457200.001]
  • [Cites] Radiology. 2000 Aug;216(2):403-9 [10924561.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] AJR Am J Roentgenol. 2005 May;184(5):1535-40 [15855112.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):582-7 [16163023.001]
  • [Cites] Radiology. 1997 Mar;202(3):655-62 [9051012.001]
  • [Cites] Radiology. 1995 May;195(2):353-7 [7724752.001]
  • [Cites] Br J Radiol. 2004 Oct;77(922):821-30 [15482993.001]
  • [Cites] Radiology. 1999 Jul;212(1):219-25 [10405745.001]
  • [Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]
  • [Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]
  • (PMID = 18677610.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; JR13W81H44 / Iopamidol
  •  go-up   go-down


48. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SP: Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia; 2006 Apr;8(4):279-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.
  • The aim of this study is to examine the Wnt/beta-catenin pathway in patients with advanced pancreatic adenocarcinoma (n = 31).
  • Thus, Wnt/beta-catenin activation was observed in 65% of pancreatic adenocarcinomas, independently of beta-catenin gene mutations in most tumors.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Digestion. 1999 Nov-Dec;60(6):544-8 [10545724.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):285-302 [16012954.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6776-84 [10597286.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] J Med Invest. 2000 Feb;47(1-2):47-55 [10740979.001]
  • [Cites] Development. 2001 Mar;128(6):871-81 [11222142.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3245-9 [11309273.001]
  • [Cites] Hepatology. 2001 May;33(5):1098-109 [11343237.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):37-52 [11467451.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5857-68 [11486025.001]
  • [Cites] Development. 2005 Nov;132(21):4663-74 [16192304.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):459-65 [16099633.001]
  • [Cites] Cancer Lett. 2006 Feb 28;233(2):328-37 [15893416.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1219-32 [11579131.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4127-34 [11911306.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2064-71 [11929826.001]
  • [Cites] Science. 2002 May 31;296(5573):1644-6 [12040179.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2015-27 [12174879.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] Dev Dyn. 2002 Nov;225(3):260-70 [12412008.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8293-301 [12447692.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):838-43; discussion 844 [12504222.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):202-16 [12512043.001]
  • [Cites] J Pathol. 2003 Feb;199(2):185-90 [12533831.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:199-231 [12195027.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):586-92 [12566300.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):621-5 [12642683.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Hepatology. 2003 Apr;37(4):824-32 [12668975.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):284-90 [12679314.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):161-70 [12706873.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Trends Cell Biol. 2003 Jun;13(6):328-35 [12791299.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 18;307(1):188-97 [12849999.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Gene Expr. 2003;11(3-4):141-7 [14686787.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1134-46 [15057752.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):757-66 [8425900.001]
  • [Cites] Trends Genet. 1993 Sep;9(9):317-21 [8236461.001]
  • [Cites] Oncogene. 1995 Jan 5;10(1):177-84 [7824270.001]
  • [Cites] Development. 1995 Nov;121(11):3529-37 [8582267.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3286-305 [9407023.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 29;247(3):851-8 [9647782.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):325-9 [10027390.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):431-6 [10201374.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):504-11 [10404062.001]
  • [Cites] Semin Liver Dis. 1999;19(3):235-42 [10518303.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1253-6 [10523691.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Hepatol. 2005 Jul;43(1):132-41 [15893845.001]
  • [Cites] Adv Cancer Res. 2000;77:1-24 [10549354.001]
  • (PMID = 16756720.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK062277; United States / NIDDK NIH HHS / DK / 1R01DK62277
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC1600679
  •  go-up   go-down


49. Koizumi K, Fujii T, Matsumoto A, Sugiyama R, Suzuki S, Sukegawa R, Ozawa K, Orii F, Taruishi M, Saitoh Y, Sotokawa M, Takada A: [Synchronous double invasive ductal carcinomas of the pancreas with multifocal branch duct intraductal papillary mucinous neoplasms of the pancreas]. Nihon Shokakibyo Gakkai Zasshi; 2009 Jan;106(1):98-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous double invasive ductal carcinomas of the pancreas with multifocal branch duct intraductal papillary mucinous neoplasms of the pancreas].
  • CT scan revealed double tumors in the pancreatic head and body concomitant with multicystic lesions of the pancreas.
  • Final histological diagnosis was double invasive ductal carcinomas of the pancreas head and tail with multifocal branch duct intraductal papillary mucinous adenomas of the pancreas.
  • The present case suggests that entire pancreas might have malignant potential in patients with intraductal papillary mucinous neoplasms.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Neoplasms, Multiple Primary. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122428.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Yango J, Pieters T, Coche E, Lambert M: [Increased serum CA 19.9 in bronchiectasis]. Rev Mal Respir; 2008 Jan;25(1):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Elévation du CA 19.9 sérique et bronchectasies.
  • INTRODUCTION: CA 19.9 is considered the most specific and sensitive serological marker of pancreatic adenocarcinoma.
  • Exhaustive investigation and clinical evolution excluded a neoplastic digestive disorder but positron emission tomography revealed a distinct hypermetabolic focus in the area of the hilum of the right lung.
  • [MeSH-major] Bronchiectasis / diagnosis. CA-19-9 Antigen / blood
  • [MeSH-minor] Aged. Biomarkers / blood. Female. Haemophilus Infections / diagnosis. Haemophilus Infections / immunology. Haemophilus influenzae / immunology. Haemophilus influenzae / isolation & purification. Humans

  • Genetic Alliance. consumer health - Bronchiectasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288056.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-19-9 Antigen
  •  go-up   go-down


51. Chen J, Röcken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, Malfertheiner P, Ebert MP: The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett; 2006 Feb 28;233(2):328-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
  • Pancreatic cancers express KIT and PDGFRs.
  • Therefore, 26 patients with unresectable pancreatic cancer were randomized to either gemcitabine (1000 mg/m2 weekly) or imatinib (2x400 mg po) treatment daily.
  • Pancreatic adenocarcinoma was confirmed histologically and expression of KIT and PDGFRbeta was determined immunohistochemically in the biopsy specimens.
  • In this small series of pancreatic cancer patients, treatment with imatinib was not associated with a significant control of cancer progression.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pancreatic Neoplasms / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Benzamides. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Female. Humans. Imatinib Mesylate. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Male. Middle Aged. Proto-Oncogene Proteins c-kit / metabolism. Quality of Life. Receptors, Platelet-Derived Growth Factor / metabolism. Surveys and Questionnaires. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893416.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0W860991D6 / Deoxycytidine; 8A1O1M485B / Imatinib Mesylate; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


52. Nichols MT, Russ PD, Chen YK: Pancreatic imaging: current and emerging technologies. Pancreas; 2006 Oct;33(3):211-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic imaging: current and emerging technologies.
  • This review discusses the current imaging modalities for the diagnosis and staging of solid and cystic pancreatic lesions and for the assessment of acute and chronic pancreatitis, and the future role of emerging technologies in the management of pancreatic diseases.
  • Multidetector row spiral computed tomography is superior to conventional single-detector row spiral computed tomography in the detection and staging of pancreatic adenocarcinoma.
  • Positron emission tomography-computed tomography fusion may improve the staging accuracy for pancreatic cancer.
  • Echo-enhanced ultrasound may have an emerging role in evaluating pancreatic masses.
  • Endoscopic ultrasound with fine needle aspiration for cytology is the single best method for diagnosis and staging of nonmetastatic pancreatic cancer with a high accuracy for determining tumor resectability.
  • Secretin-stimulated imaging techniques may eventually provide a noninvasive method of reliably assessing pancreatic exocrine function.
  • [MeSH-major] Pancreatic Diseases / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Acute Disease. Biopsy, Fine-Needle. Chronic Disease. Humans. Pancreatitis / diagnosis. Pancreatitis / pathology. Pancreatitis / radiography. Pancreatitis / ultrasonography. Positron-Emission Tomography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17003640.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


53. Xu J, Liang Z, Hao S, Zhu L, Ashish M, Jin C, Fu D, Ni Q: Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging. Abdom Imaging; 2009 Nov;34(6):759-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging.
  • Thus, in lesions of the tissues of the pancreas, this offers to increase the accuracy of CT diagnosis.
  • In this study, our aim was to explore the perfusion characteristics of normal pancreas and pancreatic adenocarcinoma.
  • METHODS: Dynamic 64-slice helical CT was conducted in 36 patients with non-pancreatic disease and in 40 patients with histopathologically proven pancreatic adenocarcinoma.
  • RESULTS: There was no significant difference noted between the distribution of BF, BV, and PS values in different regions of the pancreas, namely the head, neck, body, and tail (P > 0.05).
  • The BF, BV, and PS of normal pancreas were recorded as 135.24 +/- 48.36 ml min(-1) 100 g(-1), 200.55 +/- 54.96 ml 100 g(-1), and 49.75 +/- 24.27 ml min(-1) 100 g(-1), respectively.
  • BF, BV, and PS values of the tumor tissue of pancreatic adenocarcinoma decreased significantly compared to normal pancreas (P < 0.05).
  • CONCLUSIONS: Normal pancreas appears homogenous on perfusion CT.
  • A significant decrease of BF, BV, and PS was observed in pancreatic adenocarcinoma.
  • Dynamic 64-slice helical CT with perfusion imaging should be considered a potential modality to increase the accuracy of CT diagnosis for pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Case-Control Studies. Contrast Media. Female. Humans. Iohexol. Male. Middle Aged. Pancreas / blood supply. Pancreas / radiography. Pancreaticoduodenectomy. Prospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672566.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


54. Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, Curley SA: Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res; 2010 Dec 1;16(23):5712-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.
  • PURPOSE: Pancreatic carcinoma is one of the deadliest cancers with few effective treatments.
  • We used the astounding heating rates of AuNPs in nonionizing radiofrequency (RF) radiation to investigate human pancreatic xenograft destruction in a murine model.
  • EXPERIMENTAL DESIGN: Weekly, Panc-1 and Capan-1 human pancreatic carcinoma xenografts in immunocompromised mice were exposed to an RF field 36 hours after treatment (intraperitoneal) with cetuximab- or PAM4 antibody-conjugated AuNPs, respectively.
  • Cetuximab- and PAM4-conjugated AuNPs demonstrated RF field-induced destruction of Panc-1 and Capan-1 pancreatic carcinoma xenografts after 6 weeks of weekly treatment (P = 0.004 and P = 0.035, respectively).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S [14506191.001]
  • [Cites] J Biomed Opt. 2000 Oct;5(4):383-90 [11092426.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 2):2245-51 [445424.001]
  • [Cites] Ann Clin Lab Sci. 1981 Sep-Oct;11(5):386-91 [7036839.001]
  • [Cites] J Urol. 1989 Nov;142(5):1364-8 [2810532.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(4):343-9 [2106751.001]
  • [Cites] Am J Pathol. 1996 Oct;149(4):1271-86 [8863675.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):746-51 [9579539.001]
  • [Cites] Lasers Surg Med. 1998;23(4):194-203 [9829430.001]
  • [Cites] Langmuir. 2005 Nov 8;21(23):10644-54 [16262332.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S45-53 [16447274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18882-6 [17135351.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5225-32 [18024868.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2654-65 [17960610.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7380-7 [18094420.001]
  • [Cites] Nat Protoc. 2008;3(2):314-20 [18274533.001]
  • [Cites] Biophys J. 2008 May 15;94(10):3790-7 [18234813.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4819-26 [18559529.001]
  • [Cites] Surgery. 2008 Aug;144(2):125-32 [18656617.001]
  • [Cites] J Exp Ther Oncol. 2008;7(4):313-26 [19227011.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):836-47 [19194760.001]
  • [Cites] World J Gastroenterol. 2009 Jun 28;15(24):2995-3002 [19554652.001]
  • [Cites] Small. 2009 Jul;5(13):1553-61 [19326357.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Radiat Biol. 2009 Dec;85(12):1114-25 [19995237.001]
  • [Cites] Adv Drug Deliv Rev. 2010 Mar 8;62(3):339-45 [19909777.001]
  • [Cites] J Surg Oncol. 2010 Mar 15;101(4):315-20 [20187063.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 May 15;245(1):116-23 [20193702.001]
  • [Cites] Cancer. 2010 Jul 1;116(13):3285-93 [20564640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13549-54 [14597719.001]
  • (PMID = 21138869.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA151668-02; United States / NCI NIH HHS / CA / T32 CA09599; United States / NCI NIH HHS / CA / CA016672; United States / NCI NIH HHS / CA / U54 CA151668; United States / NCI NIH HHS / CA / T32 CA009599-21; United States / NCI NIH HHS / CA / U54 CA143837; United States / NCI NIH HHS / CA / U54CA143837; United States / NCI NIH HHS / CA / U54 CA151668-02; United States / NCI NIH HHS / CA / T32 CA009599
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 7440-57-5 / Gold; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ NIHMS245136; NLM/ PMC3057504
  •  go-up   go-down


55. Chen B, Hu S, Wang L, Wachtel MS, Frezza EE: Extended pancreatectomy with en bloc resection of the celiac axis for locally advanced cancer of pancreatic body and tail. Hepatogastroenterology; 2008 Nov-Dec;55(88):2252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pancreatectomy with en bloc resection of the celiac axis for locally advanced cancer of pancreatic body and tail.
  • At present, most surgeons will not resect the pancreas if there is involvement of celiac axis.
  • We present the case of a 67 yo male with pancreatic body and tail cancer invading the celiac axis treated by extended pancreatectomy, splenectomy, partial resection of proximal portion of jejunum and transverse colon, and left adrenalectomy with en bloc resection of celiac axis.
  • The case demonstrates that a procedure that may offer cure of locally advanced pancreas cancer may also completely resolve abdominal pain.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260516.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


56. Prenzel KL, Warnecke-Eberz U, Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Drebber U, Hoelscher AH, Schneider PM: Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. World J Gastroenterol; 2006 Jan 21;12(3):437-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater.
  • AIM: We examined quantitative mRNA expression of growth factor receptors (c-erbB-1, c-erbB-2) and the anti-apoptosis gene survivin known to be regulated in pancreatic adenocarcinomas and compared the expression pattern with that in carcinomas of the papilla of Vater.
  • METHODS: Quantitative real-time reverse transcriptase-PCR (QRT-PCR, Taqman) was performed to analyze mRNA expression levels of c-erbB-1, c-erbB-2 and survivin in normal and corresponding tumor samples of 31 pancreatic adenocarcinomas and 8 cancers of the papilla of Vater.
  • RESULTS: The overall median mRNA expression of survivin was significantly increased in both adenocarcinoma of the pancreas (P<0.01) and papilla of Vater (P<0.008) compared with uninvolved normal control tissue.
  • In pancreatic cancer, expression of c-erbB-1 was significantly decreased compared with the normal pancreatic tissue (P<0.03), whereas in the cancer of the papilla of Vater expression of c-erbB-2 was significantly downregulated (P<0.05) compared with the paired normal samples.
  • CONCLUSION: The common anti-apoptosis gene survivin is overexpressed both in the cancer of the papilla of Vater and pancreas.
  • In contrast, the growth factor receptor genes c-erbB-1 and c-erbB-2 are differentially regulated in both tumor entities adding further evidence that pancreatic cancer is biologically different from the cancer of papilla of Vater.
  • [MeSH-major] Adenocarcinoma / metabolism. Ampulla of Vater. Common Bile Duct Neoplasms / metabolism. Pancreatic Neoplasms / metabolism. RNA, Messenger / genetics. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):767-74; discussion 774-5 [10615931.001]
  • [Cites] Oncol Rep. 2005 Jun;13(6):1241-6 [15870949.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):393-8 [10666367.001]
  • [Cites] Gut. 2000 May;46(5):645-50 [10764707.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):103-6 [10853025.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):469-74 [11102889.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Lab Invest. 1999 Nov;79(11):1327-33 [10576203.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2422-32 [11331321.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):305-10 [11352303.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):677-85 [11455000.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):271-8 [11466679.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):496-9 [11586103.001]
  • [Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):1-23 [11719025.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):886-92 [11953819.001]
  • [Cites] Med Electron Microsc. 2001 Dec;34(4):207-12 [11956993.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):1-11 [12021893.001]
  • [Cites] Stat Methods Med Res. 2002 Jun;11(3):247-74 [12094758.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1593-7 [12168842.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8581-9 [14634620.001]
  • [Cites] Pediatr Dev Pathol. 2003 Sep-Oct;6(5):392-7 [14708732.001]
  • [Cites] J Immunol. 2004 Mar 15;172(6):3922-9 [15004200.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):334-7 [15086152.001]
  • [Cites] Pancreas. 2004 Jul;29(1):e1-8 [15211117.001]
  • [Cites] Surgery. 2004 Aug;136(2):443-8 [15300213.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2759-61 [15309737.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Radiology. 1973 Nov;109(2):297-303 [4742316.001]
  • [Cites] Ann R Coll Surg Engl. 1985 May;67(3):139-43 [2988399.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):957-61 [3664230.001]
  • [Cites] Cell. 1990 Apr 20;61(2):203-12 [2158859.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):2973-82 [2342466.001]
  • [Cites] J Pathol. 1990 Jul;161(3):195-200 [2202801.001]
  • [Cites] J Pathol. 1991 Feb;163(2):111-6 [1707959.001]
  • [Cites] Prog Growth Factor Res. 1992;4(1):1-24 [1355372.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Anticancer Res. 1993 May-Jun;13(3):565-9 [8317885.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):418-25 [7901825.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):786-92 [8206673.001]
  • [Cites] Cell. 1994 Jul 15;78(1):5-8 [8033211.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Oncology. 1995 Sep-Oct;52(5):392-6 [7637957.001]
  • [Cites] Int J Pancreatol. 1995 Feb;17(1):15-21 [8568330.001]
  • [Cites] J Urol. 1996 Jan;155(1):321-6 [7490879.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Genome Res. 1996 Oct;6(10):995-1001 [8908519.001]
  • [Cites] Eur J Surg Oncol. 1997 Feb;23(1):30-5 [9066744.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5B):3841-7 [9427790.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):17-31 [10638554.001]
  • (PMID = 16489645.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC4066064
  •  go-up   go-down


57. Wada K, Takada T, Amano H, Yoshida M, Miura F, Toyota N, Kato K, Isaka T, Nagashima I: [Trend in the management of pancreatic adenocarcinoma--Japan vs. US and Europe]. Nihon Geka Gakkai Zasshi; 2006 Jul;107(4):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend in the management of pancreatic adenocarcinoma--Japan vs. US and Europe].
  • Pancreatic adenocarcinoma remains to have poor prognosis.
  • Current rationale for the treatment of pancreatic adenocarcinoma in the US and European countries consists of the following formula:.
  • The efficacy of "Japanese" radical resection including vascular resection or pancreatic nerve plexus resection should be evaluated, although the devise of novel diagnostic modalities and more effective adjuvant or neoadjuvant therapy are crucial to improve prognosis of this disease.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878412.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


58. Duffy A, Capanu M, Allen P, Kurtz R, Olson SH, Ludwig E, Klimstra DS, O'Reilly EM: Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol; 2009 Jul 1;100(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center.
  • BACKGROUND: There is a dearth of data in a younger population of patients with pancreatic ductal adenocarcinoma (PAC) regarding epidemiology, genetics, prognosis, and outcome.
  • RESULTS: One hundred thirty-six cases of PAC, age <or=45 years at diagnosis, were identified.
  • [MeSH-major] Adenocarcinoma / mortality. Pancreatic Neoplasms / mortality

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19384918.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Furukawa H, Uesaka K, Boku N: Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography. Arch Surg; 2008 Mar;143(3):275-80; discussion 281
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment decision making in pancreatic adenocarcinoma: multidisciplinary team discussion with multidetector-row computed tomography.
  • HYPOTHESIS: Multidetector-row computed tomography reduces the frequency of use of other imaging methods in patients with pancreatic carcinoma.
  • PATIENTS: Two hundred thirteen patients with pancreatic carcinoma.
  • MAIN OUTCOME MEASURE: Multidetector-row computed tomography was initially performed in patients with newly diagnosed pancreatic carcinoma.
  • RESULTS: Of the 213 pancreatic carcinomas, 79 (37%) were classified as probably resectable, 127 (60%) as certainly unresectable, and 7 (3%) as probably unresectable.
  • CONCLUSIONS: Multidetector-row computed tomography provides reliable information for staging pancreatic carcinoma.
  • Multidisciplinary team discussion along with use of this noninvasive technique simplifies the diagnostic strategy for pancreatic carcinoma and decreases the need for invasive staging methods.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / radiography. Decision Making. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347275.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD: Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One; 2007 Apr 25;2(4):e392
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells.
  • Emerging evidence indicates the importance of reactivated Wnt signaling in a number of cancers, including pancreatic adenocarcinoma.
  • PRINCIPLE FINDINGS: Both Sulf proteins were upregulated in human pancreatic adenocarcinoma tumors and were broadly expressed in human pancreatic adenocarcinoma cell lines.
  • Three of four pancreatic adenocarcinoma cell lines tested exhibited autocrine Wnt signaling, in that extracellular Wnt ligands were required to initiate downstream Wnt signaling.
  • Exposure of these pancreatic adenocarcinoma cells to a catalytically inactive form of Sulf-2 or siRNA-mediated silencing of endogenous Sulf-2 inhibited both Wnt signaling and cell growth.
  • CONCLUSIONS/SIGNIFICANCE: We have identified the Sulfs as potentiators of autocrine Wnt signaling in pancreatic cancer cells and have demonstrated their contribution to the growth and tumorigenicity of these cells.
  • Since the Sulfs are extracellular enzymes, they would be attractive targets for therapy of pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1439-47 [14973553.001]
  • [Cites] Genes Cells. 2002 Feb;7(2):173-85 [11895481.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49175-85 [12368295.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):284-90 [12679314.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7 [15067127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5 [15240889.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6170-4 [15208662.001]
  • [Cites] J Neurosci Res. 2004 Sep 1;77(5):653-61 [15352211.001]
  • [Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):497-506 [15542433.001]
  • [Cites] Development. 2004 Dec;131(24):6009-21 [15563523.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):743-8 [15705870.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Mol Ther. 2005 May;11(5):724-33 [15851011.001]
  • [Cites] Mol Cancer. 2005;4(1):14 [15817123.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):459-67 [15905855.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6245-54 [16024626.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):40066-73 [16192265.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):1001-10 [16331886.001]
  • [Cites] Dev Dyn. 2006 Mar;235(3):681-90 [16425220.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4969-76 [16377625.001]
  • [Cites] BMC Biochem. 2006;7:2 [16417632.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):279-89 [16756720.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2130-44 [16762634.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6025-32 [16778174.001]
  • [Cites] Biochem J. 2006 Nov 15;400(1):63-73 [16901266.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):678-88 [17116694.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R56 [17014703.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):329-32 [10888884.001]
  • [Cites] J Clin Invest. 2001 Jul;108(2):169-73 [11457867.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):357-61 [11489926.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):30744-52 [11406624.001]
  • [Cites] Science. 2001 Aug 31;293(5535):1663-6 [11533491.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 20;306(1):293-7 [12788103.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23107-17 [12686563.001]
  • [Cites] J Cell Biol. 2003 Jul 21;162(2):341-51 [12860968.001]
  • [Cites] J Virol. 2003 Aug;77(16):8957-61 [12885912.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Gene Expr. 2003;11(3-4):141-7 [14686787.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):231-48 [14699503.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5604-11 [14645250.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • (PMID = 17460759.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL075602; United States / NIGMS NIH HHS / GM / GM57411; United States / NIGMS NIH HHS / GM / R01 GM057411; United States / NCI NIH HHS / CA / R21 CA122025; United States / NCI NIH HHS / CA / R01 CA112537; United States / NHLBI NIH HHS / HL / HL075602; United States / NCI NIH HHS / CA / CA122025; United States / NCI NIH HHS / CA / CA112537
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; EC 3.1.6.- / Sulfatases
  • [Other-IDs] NLM/ PMC1849966
  • [General-notes] NLM/ Original DateCompleted: 20070803
  •  go-up   go-down


61. Buchholz M, Braun M, Heidenblut A, Kestler HA, Klöppel G, Schmiegel W, Hahn SA, Lüttges J, Gress TM: Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene; 2005 Oct 6;24(44):6626-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions.
  • Pancreatic ductal adenocarcinoma (PDAC) carries the most dismal prognosis of all solid tumours.
  • Putative precursor lesions, termed pancreatic intraepithelial neoplasia (PanIN), are classified into three different grades (PanIN-1 through -3) based on the degree of cellular atypia they display.
  • We have conducted large-scale expression profiling analyses of microdissected cells from normal pancreatic ducts, PanINs of different grades and PDACs using whole-genome oligonucleotide microarrays.
  • Our results identify a large number of potential target genes for the development of novel molecular diagnostic and therapeutic tools for the prevention and early diagnosis of PDAC and provide novel insights into the pathophysiological mechanisms involved in tumour progression in the pancreas.
  • [MeSH-major] Carcinoma in Situ / genetics. Pancreatic Neoplasms / genetics. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103885.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger
  •  go-up   go-down


62. Angst E, Sibold S, Tiffon C, Weimann R, Gloor B, Candinas D, Stroka D: Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer. Br J Cancer; 2006 Aug 7;95(3):307-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer.
  • Pancreatic ductal adenocarcinoma, called pancreatic cancer, is a highly aggressive cancer that is characterised by its avascular structure, which results in a severe hypoxic environment.
  • In this study, we investigated whether NDRG1 is upregulated in these tumours, thus providing a novel marker for malignant cells in the pancreas.
  • By immunohistochemistry, we observed that NDRG1 was highly expressed in well-differentiated cells of pancreatic cancer, whereas the poorly differentiated tumour cells were negative.
  • In addition, hyperplastic islets and ducts of nonquiescent pancreatic tissue were positive.
  • To further explore its selective expression in tumours, two well-established pancreatic cancer cell lines of unequal differentiation status were exposed to 2% oxygen.
  • Taken together, our data suggest that NDRG1 will not serve as a reliable marker of tumour cells in the pancreas, but may serve as a marker of differentiation.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Cell Cycle Proteins / genetics. Cell Differentiation. Cell Hypoxia. Gene Expression Regulation, Neoplastic / genetics. Intracellular Signaling Peptides and Proteins / genetics. Pancreatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 1997 Jul;77(1):85-92 [9251681.001]
  • [Cites] J Cell Biochem. 2006 Apr 1;97(5):1025-35 [16288478.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2182-9 [9605764.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92 [9653127.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4439-44 [9766676.001]
  • [Cites] Biochim Biophys Acta. 1999 Jul 8;1450(3):364-73 [10395947.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7655-60 [15520163.001]
  • [Cites] Surgery. 2005 Feb;137(2):192-9 [15674201.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2768-73 [15814659.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3711-21 [10589791.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):38-41 [10646848.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):749-55 [10676663.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 16;276(1):321-8 [11006124.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):919-22 [11072146.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] FASEB J. 2001 May;15(7):1312-4 [11344124.001]
  • [Cites] Surg Oncol. 2000 Nov;9(3):95-101 [11356337.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2145-51 [11448934.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 9;288(4):882-6 [11688991.001]
  • [Cites] Mol Carcinog. 2001 Oct;32(2):100-9 [11746822.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1734-41 [11865053.001]
  • [Cites] Med Oncol. 2001;18(4):243-59 [11918451.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):7021-6 [12011461.001]
  • [Cites] Cell Biol Toxicol. 2002;18(2):87-96 [12046693.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1914-9 [12085186.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:783-8 [12429530.001]
  • [Cites] Histochem Cell Biol. 2002 Nov;118(5):399-408 [12432451.001]
  • [Cites] Pancreas. 2003 Jan;26(1):56-64 [12499918.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1441-4 [12670886.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1731-6 [12702552.001]
  • [Cites] Oncogene. 2003 May 22;22(21):3213-20 [12761491.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):222-7 [14734473.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4721-7 [14981919.001]
  • [Cites] J Surg Res. 2004 Aug;120(2):295-303 [15234226.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:12 [12605718.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5675-81 [15184886.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5876-81 [15313932.001]
  • [Cites] Aerosp Med. 1973 Jun;44(6):636-8 [4708612.001]
  • [Cites] Am J Surg. 1983 Jun;145(6):813-8 [6305226.001]
  • [Cites] J Biol Chem. 1993 Oct 15;268(29):21513-8 [8408001.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3610-5 [8260699.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29659-65 [8939898.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5754-7 [8971187.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3296-302 [15867226.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7220-5 [16243791.001]
  • [Cites] J Biol Chem. 1997 Sep 5;272(36):22642-7 [9278421.001]
  • (PMID = 16832411.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2360652
  •  go-up   go-down


63. Song SJ, Lee JM, Kim YJ, Kim SH, Lee JY, Han JK, Choi BI: Differentiation of intraductal papillary mucinous neoplasms from other pancreatic cystic masses: comparison of multirow-detector CT and MR imaging using ROC analysis. J Magn Reson Imaging; 2007 Jul;26(1):86-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of intraductal papillary mucinous neoplasms from other pancreatic cystic masses: comparison of multirow-detector CT and MR imaging using ROC analysis.
  • PURPOSE: To compare the diagnostic performance of multirow-detector computed tomography (MDCT) and magnetic resonance imaging (MRI) in the differentiation of intraductal papillary mucinous neoplasms (IPMNs) from other pancreatic cystic masses.
  • MATERIALS AND METHODS: A total of 53 patients with pathologically proven pancreatic cystic lesions who had undergone MDCT and MRI were included in this study.
  • CONCLUSION: Pancreatic MRI shows better diagnostic performance than MDCT for differentiating IPMNs from other cystic lesions of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Papillary / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Cyst / diagnosis. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. ROC Curve

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17659551.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, Fujita H, Nakata K, Tanaka M: MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol; 2010 Dec;17(12):3120-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma.
  • BACKGROUND: Detection of aberrant microRNA (miR) expression may contribute to diagnosis and prognosis of various cancers.
  • The aim of this study is to evaluate the correlation between miR-203 expression and prognosis of patients with pancreatic adenocarcinoma after curative resection.
  • METHODS: A total of 113 formalin-fixed paraffin-embedded tissue samples of pancreatic adenocarcinoma, 20 samples of chronic pancreatitis, and 8 samples of normal pancreas were obtained.
  • RESULTS: miR-203 was overexpressed in pancreatic adenocarcinoma samples compared with chronic pancreatitis (P < 0.001) and normal pancreas (P = 0.001) samples.
  • An association between miR-203 expression and clinicopathological factors of pancreatic adenocarcinoma was not observed.
  • CONCLUSIONS: miR-203 expression is a new prognostic marker in pancreatic adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. MicroRNAs / genetics. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / metabolism. Pancreas / pathology. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20652642.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN203 microRNA, human; 0 / MicroRNAs; 0 / RNA, Messenger
  •  go-up   go-down


65. Sanchez SE, Trevino JG: Current adjuvant and targeted therapies for pancreatic adenocarcinoma. Curr Med Chem; 2008;15(17):1674-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current adjuvant and targeted therapies for pancreatic adenocarcinoma.
  • Pancreatic cancer is one of the deadliest malignancies, costing the lives of more than 30,000 patients every year.
  • Gemcitabine is currently considered to be the standard of care for the treatment of advanced pancreatic cancer.
  • In this paper we present an overview of the current treatment options for the different presenting stages of pancreatic cancer, including adjuvant, neoadjuvant, and targeted therapies, and attempt to provide a comprehensive analysis of the disparate research indicated on this front.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adjuvants, Pharmaceutic / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673217.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Pharmaceutic
  • [Number-of-references] 76
  •  go-up   go-down


66. Wong JC, Lu DS: Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol; 2008 Dec;6(12):1301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of pancreatic adenocarcinoma by imaging studies.
  • Imaging studies play a crucial role in the diagnosis and management of patients with pancreatic adenocarcinoma.
  • Computed tomography (CT) is the most widely available and best-validated modality for imaging patients with pancreatic adenocarcinoma.
  • To maximize the diagnostic efficacy of CT, use of a pancreas protocol is mandatory.
  • The sensitivity of CT for diagnosis of pancreatic adenocarcinoma (89%-97%) and its positive predictive value for predicting unresectability (89%-100%) are high.
  • Magnetic resonance imaging has not been shown to perform better than CT for the diagnosis and staging of pancreatic adenocarcinoma, but can be helpful as an adjunct to CT, particularly for evaluation of small hepatic lesions that cannot be fully characterized by CT.
  • Ultrasound is often the first study obtained in patients with obstructive jaundice or unexplained abdominal pain, but its utility for diagnosis and staging of patients with pancreatic adenocarcinoma is limited.
  • Positron emission tomography/CT combines the functional information provided by positron emission tomography with the anatomic information provided by CT and is a promising modality for imaging of patients with pancreatic adenocarcinoma, but its utility has not been established.
  • Endoscopic ultrasound is generally considered superior to CT for the diagnosis and local staging of pancreatic cancer, but is limited by availability and inability to assess for distant metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Pancreas / radiography. Pancreas / ultrasonography. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948228.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


67. Naito Y, Kinoshita H, Okabe Y, Arikawa S, Higaki K, Morimitsu Y, Yamasaki F, Suda K, Yasumoto M, Kusano H, Nakashima O, Yano H: Pathomorphologic study of undifferentiated carcinoma in seven cases: relationship between tumor and pancreatic duct epithelium. J Hepatobiliary Pancreat Surg; 2009;16(4):478-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathomorphologic study of undifferentiated carcinoma in seven cases: relationship between tumor and pancreatic duct epithelium.
  • BACKGROUND/PURPOSE: By the time undifferentiated carcinoma is detected, it has formed a large mass, and it is reportedly difficult to pathologically observe its relationship with the pancreatic duct.
  • In this study, we examined the pancreatic ducts of seven patients of surgical samples, and pathomorphologically investigated the relationship between the adenocarcinomatous and sarcomatous components and the pattern of tumor extension.
  • In addition, we evaluated the usefulness of pancreatic juice cytology by comparison with the findings of the main pancreatic duct (MPD).
  • METHODS: Seven primary undifferentiated carcinomas of the pancreas (from three male and four female patients with a mean age of 59 years) were analyzed.
  • Pancreatic juice cytology was performed and evaluated in two patients.
  • In one of these three, the tumor presented intraductal growth in the MPD, and preoperative pancreatic juice cytology revealed atypical cells with osteoclast-like giant cells.
  • (1) invasion and expansive growth during the sarcomatous transformation of adenocarcinoma, and (2) intraductal extension.
  • Of note, postoperative pancreatic juice cytology may be useful for the diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Abdominal Pain / etiology. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Pancreatic Juice / cytology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367361.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, Batra SK: MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res; 2007 Apr;5(4):309-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins.
  • MUC4, a transmembrane mucin, is aberrantly expressed in pancreatic adenocarcinomas while remaining undetectable in the normal pancreas.
  • Recent studies have shown that the expression of MUC4 is associated with the progression of pancreatic cancer and is inversely correlated with the prognosis of pancreatic cancer patients.
  • In the present study, we have examined the phenotypic and molecular consequences of MUC4 silencing with an aim of establishing the mechanistic basis for its observed role in the pathogenesis of pancreatic cancer.
  • The silencing of MUC4 expression was achieved by stable expression of a MUC4-specific short hairpin RNA in CD18/HPAF, a highly metastatic pancreatic adenocarcinoma cell line.
  • Consistent with our previous observation, inhibition of MUC4 expression restrained the pancreatic tumor cell growth and metastasis as shown in an orthotopic mouse model.
  • In conclusion, our study provides experimental evidence that supports the functional significance of MUC4 in pancreatic cancer progression and indicates a novel role for MUC4 in cancer cell signaling.
  • [MeSH-major] Extracellular Matrix Proteins / metabolism. Gene Expression Regulation, Neoplastic. Mucins / physiology. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17406026.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD18; 0 / Extracellular Matrix Proteins; 0 / Integrins; 0 / MUC4 protein, human; 0 / Muc4 protein, mouse; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


69. Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y: Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol; 2008 Apr;134(4):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.
  • PURPOSE: Pim-3, a member of the proto-oncogene Pim family with serine/threonine kinase activity was aberrantly expressed in cancerous lesions of endoderm-derived organs such as liver, pancreas, and colon.
  • CONCLUSIONS: Aberrant Pim-3 expression was involved in gastric adenoma-adenocarcinoma sequence and subsequent invasion and metastasis process in gastric cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenoma / chemistry. Protein-Serine-Threonine Kinases / analysis. Proto-Oncogene Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1560-3 [14571786.001]
  • [Cites] J Surg Oncol. 2007 Aug 1;96(2):95-101 [17443727.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):209-18 [15540201.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):376-80 [15900596.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):201-5 [11756242.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):241-52 [15799824.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):499-516 [12134615.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(11):3897-908 [12748291.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4536-44 [14982870.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):242-8 [15543611.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):321-8 [17270021.001]
  • [Cites] Pathol Int. 2003 Oct;53(10 ):659-66 [14516315.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):647-51 [10492641.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):507-18 [14655756.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):16-26 [11197247.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):16535-43 [9632723.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] EMBO J. 1999 Jun 15;18(12):3359-69 [10369676.001]
  • [Cites] Cell Oncol. 2005;27(4):215-23 [16308470.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2618-24 [16200194.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6741-7 [16818649.001]
  • [Cites] Croat Med J. 2007 Apr;48(2):207-17 [17436385.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] Hepatogastroenterology. 2006 Jul-Aug;53(70):484-90 [16995446.001]
  • (PMID = 17876606.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / PIM3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


70. Hamacher R, Schmid RM, Saur D, Schneider G: Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer; 2008;7:64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic pathways in pancreatic ductal adenocarcinoma.
  • Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer related death.
  • Despite the advances in understanding of the molecular pathogenesis, pancreatic cancer remains a major unsolved health problem.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Pancreatic Ductal / metabolism. Pancreatic Neoplasms / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2007 Aug 3;282(31):22551-62 [17553788.001]
  • [Cites] J Clin Pathol. 2007 Aug;60(8):885-95 [16775116.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):695-701 [17671722.001]
  • [Cites] Curr Mol Med. 2007 Aug;7(5):504-21 [17691965.001]
  • [Cites] Br J Cancer. 2007 Aug 20;97(4):523-30 [17622249.001]
  • [Cites] J Surg Res. 2007 Oct;142(2):281-6 [17640673.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Sep;7(9):1255-64 [17892425.001]
  • [Cites] Curr Opin Immunol. 2007 Oct;19(5):488-96 [17629468.001]
  • [Cites] Oncogene. 2007 Oct 25;26(49):7006-16 [17471230.001]
  • [Cites] Recent Results Cancer Res. 2008;177:151-64 [18084957.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):61-70 [18075512.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):609-17 [18026799.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1470-7 [18316571.001]
  • [Cites] Annu Rev Pathol. 2008;3:157-88 [18039136.001]
  • [Cites] Science. 1997 Oct 24;278(5338):687-9 [9381178.001]
  • [Cites] Ann N Y Acad Sci. 1999;887:150-63 [10668471.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):368-79 [10714630.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):58-66 [10739652.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6817-30 [17072330.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3265-73 [17094439.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5477-86 [11114725.001]
  • [Cites] Int J Oncol. 2001 Feb;18(2):311-6 [11172597.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] J Gastrointest Surg. 2001 Nov-Dec;5(6):603-12; discussion 612-3 [12086898.001]
  • [Cites] Pancreatology. 2001;1(3):254-62 [12120204.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):71-6 [12138400.001]
  • [Cites] Surgery. 2002 Aug;132(2):127-34 [12219002.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):2052-63 [12454861.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):989-97 [12481421.001]
  • [Cites] Int J Cancer. 2003 Apr 20;104(4):469-76 [12584745.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1365-70 [12618762.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):71-8 [12622417.001]
  • [Cites] Oncogene. 2003 May 22;22(21):3243-51 [12761494.001]
  • [Cites] Int J Cancer. 2003 Jul 20;105(6):735-46 [12767057.001]
  • [Cites] Cancer Sci. 2003 May;94(5):467-72 [12824895.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):391-7 [12865934.001]
  • [Cites] Int J Gastrointest Cancer. 2003;33(1):15-26 [12909735.001]
  • [Cites] Pancreas. 2003 Oct;27(3):e57-62 [14508142.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1714-21 [14583775.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8543-67 [14634618.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2110-5 [14647146.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1):90-119 [14970941.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):125-32 [14996497.001]
  • [Cites] Pancreas. 2008 Apr;36(3):225-35 [18362834.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2944-51 [18413764.001]
  • [Cites] Biochim Biophys Acta. 2008 May;1783(5):941-52 [18191642.001]
  • [Cites] Cell Death Differ. 2008 Jun;15(6):977-87 [18369371.001]
  • [Cites] J Exp Med. 2000 May 15;191(10):1721-34 [10811865.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3117-22 [10866296.001]
  • [Cites] J Cell Biochem. 2000 Sep 7;79(3):355-69 [10972974.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5451-5 [11034087.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4258-69 [11464292.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):271-8 [11466679.001]
  • [Cites] J Pathol. 2001 Aug;194(4):444-50 [11523052.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3269-75 [11595724.001]
  • [Cites] Pancreas. 2001 Oct;23(3):251-8 [11590320.001]
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 15):2735-46 [11683408.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):886-92 [11953819.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):893-8 [11953820.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):277-88 [12001989.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1741-9 [9563493.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] Oncology. 1999;56(1):73-82 [9885381.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):119-27 [9918209.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2351-62 [15476283.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8571-80 [15467756.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):307-15 [15549092.001]
  • [Cites] Pancreatology. 2004;4(6):567-86 [15550766.001]
  • [Cites] FASEB J. 2005 Apr;19(6):620-2 [15670977.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):287-97 [15803136.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1606-25 [15887154.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9164-8 [16230374.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):3967-72 [16309185.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):921-9 [16341083.001]
  • [Cites] J Cell Biochem. 2006 Jan 1;97(1):98-108 [16173075.001]
  • [Cites] Curr Dir Autoimmun. 2006;9:1-17 [16394652.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2778-84 [16510599.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):483-93 [16546962.001]
  • [Cites] Cancer Treat Res. 2006;130:141-65 [16610707.001]
  • [Cites] Pancreas. 2006 Apr;32(3):288-96 [16628085.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1218-49 [16702400.001]
  • [Cites] World J Gastroenterol. 2006 May 14;12(18):2901-7 [16718816.001]
  • [Cites] Am J Surg Pathol. 2006 Jun;30(6):754-9 [16723855.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4798-811 [16892092.001]
  • [Cites] EMBO J. 2006 Aug 23;25(16):3801-12 [16902410.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6685-705 [17072322.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1010:510-3 [15033781.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):591-9 [15051014.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2861-74 [15077149.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2950-66 [15077156.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71 [15166955.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:6 [12605713.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:15 [12605716.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):592-603 [15286739.001]
  • [Cites] Surgery. 2004 Aug;136(2):443-8 [15300213.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2759-61 [15309737.001]
  • [Cites] J Med Chem. 2004 Aug 26;47(18):4417-26 [15317454.001]
  • [Cites] Cancer Gene Ther. 2004 Sep;11(9):633-41 [15272314.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):859-68 [11314019.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11613-22 [17178855.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62 [17183360.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):248-57 [16832350.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):957-66 [17339366.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):993-1000 [17342093.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2344-52 [17311258.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):66-75 [17304504.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4679-86 [17510394.001]
  • (PMID = 18652674.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Death Domain; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Oncogene Protein v-akt
  • [Number-of-references] 112
  • [Other-IDs] NLM/ PMC2515336
  •  go-up   go-down


71. Alldinger I, Dittert D, Peiper M, Fusco A, Chiappetta G, Staub E, Lohr M, Jesnowski R, Baretton G, Ockert D, Saeger HD, Grützmann R, Pilarsky C: Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology; 2005;5(4-5):370-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer.
  • BACKGROUND: Pancreatic cancer is one of the leading causes of cancer-related death.
  • Using DNA gene expression analysis based on a custom made Affymetrix cancer array, we investigated the expression pattern of both primary and established pancreatic carcinoma cell lines.
  • METHODS: We analyzed the gene expression of 5 established pancreatic cancer cell lines (AsPC-1, BxPC-3, Capan-1, Capan-2 and HPAF II) and 5 primary isolates, 1 of them derived from benign pancreatic duct cells.
  • Several of the upregulated genes (like Prefoldin 5, ADAM9 and E-cadherin) have been associated with pancreatic cancer before.
  • The other differentially regulated genes, however, play a so far unknown role in the course of human pancreatic carcinoma.
  • By means of immunohistochemistry we could show that thymosin beta-10 (TMSB10), upregulated in tumor cell lines, is expressed in human pancreatic carcinoma, but not in non-neoplastic pancreatic tissue, suggesting a role for TMSB10 in the carcinogenesis of pancreatic carcinoma.
  • CONCLUSION: Using gene expression profiling of pancreatic cell lines we were able to identify genes differentially expressed in pancreatic adenocarcinoma, which might contribute to pancreatic cancer development.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Down-Regulation. Gene Expression Profiling. Pancreatic Neoplasms / genetics. Up-Regulation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Male. Middle Aged. Pancreas / metabolism. Thymosin / genetics. Thymosin / metabolism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15983444.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 61512-21-8 / Thymosin; 87397-91-9 / thymosin beta(10)
  •  go-up   go-down


72. Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, Talamonti MS: Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg; 2007 Oct;205(4):558-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
  • BACKGROUND: The American Joint Committee on Cancer (AJCC) 6(th) edition staging system for pancreatic adenocarcinoma specifically excludes pancreatic neuroendocrine tumors (PNETs), and a widely accepted staging classification does not exist.
  • Our objective was to evaluate the feasibility of applying the AJCC pancreatic adenocarcinoma staging system to PNETs.
  • When comparing outcomes to those of patients with pancreatic adenocarcinoma, the estimated median survival was significantly better for resected patients with PNETs (60 versus 13 months, p < 0.0001).
  • CONCLUSIONS: When applied to PNETs, the AJCC staging system for pancreatic adenocarcinoma provides survival discrimination by stage for surgical and nonsurgical patients.
  • Survival rates are better for PNETs than for pancreatic adenocarcinoma, but the staging system can effectively stratify patients with PNETs.
  • [MeSH-major] Neoplasm Staging. Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17903729.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. O'Connor JK, Sause WT, Hazard LJ, Belnap LP, Noyes RD: Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1060-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma.
  • PURPOSE: To evaluate a single institution's experience with intraoperative radiation therapy (IORT) in combination with attempted surgical resection for pancreatic and periampullary adenocarcinoma.
  • METHODS AND MATERIALS: From May 1986 until June 2001, 77 patients at LDS Hospital underwent attempted surgical resection and IORT for pancreatic or periampullary adenocarcinoma.
  • Forty-four patients with tumors located in the pancreas and 9 patients with periampullary tumors underwent potentially curative surgical resection and IORT.
  • Twenty-four patients had pancreatic tumors deemed unresectable and underwent surgical bypass and IORT.
  • RESULTS: Patients undergoing a potentially curative resection and IORT for periampullary adenocarcinoma had a median survival of 167 months and a 56% 5-year actuarial survival, compared with a median survival of 16 months and a 19% 5-year actuarial survival for patients undergoing the same treatment for pancreatic adenocarcinoma (p = 0.03).
  • CONCLUSIONS: Intraoperative radiation therapy is well tolerated and does not increase the morbidity or mortality of potentially curative surgical resection for pancreatic or periampullary adenocarcinoma.
  • Patients with periampullary adenocarcinoma have a better prognosis than those with pancreatic adenocarcinoma, and patients with unresectable pancreatic disease fared worse.
  • [MeSH-major] Adenocarcinoma / mortality. Ampulla of Vater. Common Bile Duct Neoplasms / mortality. Pancreatic Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978737.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Goitia-Durán MB, Linhares MM, Artigiani Neto R, Apodaca-Torrez FR, Lobo EJ, Goldenberg A: Expression of p53, p16 and Ki67 proteins in ductal adenocarcinoma of the pancreatic head and their relation with survival and cell differentiation. Einstein (Sao Paulo); 2010 Dec;8(4):444-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53, p16 and Ki67 proteins in ductal adenocarcinoma of the pancreatic head and their relation with survival and cell differentiation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26760327.001).
  • [ISSN] 1679-4508
  • [Journal-full-title] Einstein (São Paulo, Brazil)
  • [ISO-abbreviation] Einstein (Sao Paulo)
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


75. Hara H, Suda K: Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma. Am J Clin Pathol; 2008 Jan;129(1):115-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma.
  • Invasive ductal adenocarcinoma (IDA) of the pancreas (IDAP) originating from the ductal gland has a poor prognosis.
  • Noninvasive carcinomas are principally intraductal papillary mucinous carcinomas (IPMCs) and pancreatic intraepithelial neoplasms 3 (PanIN-3).
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Humans. Hyperplasia / pathology. Mucins / metabolism. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089497.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


76. Soman AD, Collins JM, DePetris G, Decker GA, Silva A, Moss A, Greer W, Ashman J, Callister M, Borad MJ: Isolated supraclavicular lymph node metastasis in pancreatic adenocarcinoma: a report of three cases and review of the literature. JOP; 2010;11(6):604-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated supraclavicular lymph node metastasis in pancreatic adenocarcinoma: a report of three cases and review of the literature.
  • CONTEXT: Supraclavicular lymph nodes represent a rare site of metastasis in pancreatic cancer.
  • We report three cases of pancreatic adenocarcinoma with metastases to supraclavicular lymph nodes.
  • CASE REPORT: A 51-year-old male was diagnosed with locally advanced pancreatic adenocarcinoma on computed tomography (CT) scan.
  • The patient received systemic chemotherapy for metastatic pancreatic adenocarcinoma.
  • The second patient, a 66-year-old female with pancreatic adenocarcinoma, underwent pancreaticoduodenectomy and was found to have peripancreatic lymph node involvement.
  • PET/CT scan and biopsy revealed supraclavicular lymph node metastasis from a pancreatic adenocarcinoma primary.
  • Staging evaluations revealed a pancreatic mass for which he underwent subtotal pancreatectomy and splenectomy.
  • Histopathology revealed grade 3 pancreatic adenocarcinoma.
  • Excisional biopsy of a supraclavicular lymph node showed metastatic pancreatic adenocarcinoma.
  • CONCLUSION: In patients with pancreatic adenocarcinoma, supraclavicular lymph node metastasis represents an uncommon, but clinically significant finding that can lead to changes in treatment planning.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JOP. 2011 Jan;12(1):66-7; author reply 70 [21206107.001]
  • (PMID = 21068495.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


77. Wolfson D, Barkin JS, Chari ST, Clain JE, Bell RH Jr, Alexakis N, Neoptolemos JP: Management of pancreatic masses. Pancreas; 2005 Oct;31(3):203-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of pancreatic masses.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Preoperative Care
  • [MeSH-minor] Diagnosis, Differential. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16163050.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


78. Bao P, Potter D, Eisenberg DP, Lenzner D, Zeh HJ, Lee Iii KK, Hughes SJ, Sanders MK, Young JL, Moser AJ: Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford); 2009 Nov;11(7):606-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma.
  • BACKGROUND: The surgeon's contribution to patients with localized pancreatic adenocarcinoma (PAC) is a margin negative (R0) resection.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495714.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2785957
  •  go-up   go-down


79. Seicean A, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O: Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses. Ultraschall Med; 2010 Dec;31(6):571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses.
  • PURPOSE: Contrast-enhanced harmonic endoscopic ultrasonography (CEH-EUS) for the assessment of microcirculation and the delineation of pancreatic tumors in order to characterize and stage them has only recently become available for commercial use, and few reports have been published.
  • The purpose of the study was the qualitative and quantitative digital image analysis of pancreatic adenocarcinomas using conventional endoscopic ultrasonography (EUS) and CEH-EUS and the evaluation of whether contrast medium injection modified adenocarcinoma staging and patient management.
  • MATERIALS AND METHODS: In each of 30 prospectively examined patients with suspected pancreatic solid lesions, CEH-EUS was performed using the same quantity of the contrast agent SonoVue and a low mechanical index (0.3 - 0.4), followed by EUS-FNA.
  • The histology, based on EUS-FNA or surgery and 9 months of follow-up, was: pancreatic adenocarcinoma (n = 15), pseudotumoral chronic pancreatitis (n = 12), neuroendocrine tumor (n = 1), common bile duct tumor (n = 1), lymph node metastases of gastric cancer (n = 1).
  • RESULTS: CEH-EUS showed a hypoenhanced pattern in 14 cases of adenocarcinoma and in 10 cases of chronic pancreatitis.
  • The index of the contrast uptake ratio was significantly lower in adenocarcinoma than in mass-forming chronic pancreatitis.
  • A cut-off uptake ratio index value of 0.17 for diagnosing adenocarcinoma corresponded to an AUC (CI 95%) of 0.86 (0.67 - 1.00) with a sensitivity of 80%, a specificity of 91.7%, a positive predictive value of 92.8%, and a negative predictive value of 78%.
  • The size of the pancreatic mass was assessed significantly more effectively by CEH-EUS but adenocarcinoma staging was not modified.
  • CONCLUSION: The majority of cases of both pancreatic adenocarcinoma and chronic pancreatitis were hypoenhanced and visual discrimination was not possible.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endosonography / methods. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Pancreatic Neoplasms / ultrasonography. Tumor Burden / physiology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Microvessels / ultrasonography. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / ultrasonography. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / ultrasonography. Phospholipids. Prospective Studies. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21080306.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


80. Eltoum IA, Eloubeidi MA, Chhieng DC, Tamhane A, Crowe R, Jhala D, St John KD, Wilcox CM, Siegal GP, Vickers S, Jhala NC: Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma. Am J Clin Pathol; 2005 Nov;124(5):697-707
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic grade independently predicts survival of patients with pancreatic adenocarcinoma.
  • Our objectives were to devise a cytologic grading system and determine whether it would predict survival of patients with solid-type pancreatic adenocarcinoma.
  • We devised a grading system that independently predicted survival in patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203289.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Azure Stains; 0 / Romanowsky-Giemsa stain; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


81. Muroni M, D'Angelo F, Pezzatini M, Sebastiani S, Noto S, Pilozzi E, Ramacciato G: Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int; 2010 Feb;9(1):97-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma.
  • BACKGROUND: The association between gastric and pancreatic carcinoma is a relatively rare condition.
  • Gastric cancer associated with pancreatic cancer is uncommon.
  • Computed tomography and magnetic resonance showed a gastric thickening in the antral and pyloric portion and a nodular mass (3 X 1.7 cm) in the uncinate portion of the pancreas.
  • Histological examination of the specimen demonstrated a moderately differentiated adenocarcinoma of the stomach and a poorly differentiated ductal adenocarcinoma of the pancreas.
  • CONCLUSIONS: Long survival is rare in patients with associated gastric and pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133238.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


82. Hussain F, Wang J, Ahmed R, Guest SK, Lam EW, Stamp G, El-Bahrawy M: The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine; 2010 Feb;49(2):134-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours.
  • IL-8 has been shown to have pro-angiogenic, mitogenic and motogenic effects and several studies have demonstrated the expression of IL-8 by various human pancreatic cancer cell lines.
  • METHODS: The expression of IL-8 and IL-8 receptors was studied in 52 pancreatic adenocarcinomas and 52 pancreatic neuroendocrine tumours using immunohistochemistry.
  • The expression of IL-8 and IL-8 receptors was also assessed in eight pancreatic adenocarcinomas and seven neuroendocrine tumours in comparison to normal pancreatic tissue using real time quantitative PCR (qRT-PCR).
  • RESULTS: Immunohistochemical analysis of the expression of IL-8, IL-8RA and IL-8RB in 52 pancreatic adenocarcinomas demonstrated expression in 25%, 75% and 79% of pancreatic adenocarcinomas, respectively.
  • IL-8, IL-8RA and IL-8RB expression was detected in 21%, 63% and 92% of 52 pancreatic neuroendocrine tumours.
  • Using qRT-PCR, the expression of each of IL-8, IL-8RA and IL-8RB mRNA was increased in 75% of pancreatic adenocarcinomas.
  • IL-8, IL-8RA and IL-8RB mRNA expression was also increased in 57%, 43% and 29% of pancreatic neuroendocrine tumours.
  • Quantitatively, there was a significant increase in expression level of IL-8 in tumours of both types in comparison to normal pancreatic tissue (38.5-fold in adenocarcinomas and 43.9-fold in neuroendocrine tumours).
  • IL-8RB was slightly increased in adenocarcinomas in comparison to normal pancreas (1.4-fold), but the expression was decreased in neuroendocrine tumours compared with normal pancreas (0.9-fold).
  • CONCLUSION: This is the first study to show that IL-8 and IL-8 receptors are upregulated in both pancreatic adenocarcinomas and neuroendocrine tumours, and indicate this signalling pathway may modulate tumour behaviour through autocrine and/or paracrine loops.
  • [MeSH-major] Adenocarcinoma / metabolism. Interleukin-8 / metabolism. Neuroendocrine Tumors / metabolism. Pancreatic Neoplasms / metabolism. Receptors, Interleukin-8 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Pancreas / cytology. Pancreas / metabolism. Pancreas / pathology. Signal Transduction / physiology. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20005738.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Receptors, Interleukin-8
  •  go-up   go-down


83. Leiman G: My approach to pancreatic fine needle aspiration. J Clin Pathol; 2007 Jan;60(1):43-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] My approach to pancreatic fine needle aspiration.
  • Pancreatic fine needle aspiration cytopathology has earned a reputation as a rapid, safe, accurate and cost-beneficial modality of investigation of pancreatic mass lesion.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Pancreas / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Humans. Patient Selection

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • [Cites] Acta Cytol. 1983 Sep-Oct;27(5):500-4 [6578648.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Diagn Cytopathol. 1985 Apr-Jun;1(2):105-10 [3836074.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):69-71 [3720483.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):72-5 [3522134.001]
  • [Cites] Acta Cytol. 1986 Jul-Aug;30(4):430-4 [3461652.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):39-42 [3336955.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):43-8 [2447722.001]
  • [Cites] Acta Cytol. 1988 Jul-Aug;32(4):447-51 [3400383.001]
  • [Cites] Acta Cytol. 1992 Sep-Oct;36(5):655-60 [1523921.001]
  • [Cites] Acta Cytol. 1992 Nov-Dec;36(6):881-6 [1449026.001]
  • [Cites] Am J Clin Pathol. 1992 Nov;98(5):478-88 [1283055.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):889-93 [8249508.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):908-12 [8249512.001]
  • [Cites] AJR Am J Roentgenol. 1988 Sep;151(3):493-4 [3261508.001]
  • [Cites] Acta Radiol. 1988 Sep-Oct;29(5):535-9 [3048349.001]
  • [Cites] Acta Cytol. 1996 May-Jun;40(3):585-91 [8669201.001]
  • [Cites] Diagn Cytopathol. 1996 Jul;15(1):37-45 [8807250.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):396-410 [8834314.001]
  • [Cites] Acta Cytol. 1996 Sep-Oct;40(5):975-9 [8842177.001]
  • [Cites] Diagn Cytopathol. 1997 Feb;16(2):112-6 [9067100.001]
  • [Cites] Am Surg. 1997 Aug;63(8):675-9; discussion 679-80 [9247432.001]
  • [Cites] Am J Gastroenterol. 1998 Aug;93(8):1329-33 [9707060.001]
  • [Cites] Diagn Cytopathol. 1998 Dec;19(6):423-7 [9839131.001]
  • [Cites] Adv Anat Pathol. 1999 Mar;6(2):65-77 [10331069.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):639-42; discussion 642-3 [10367874.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):1111-5 [10425311.001]
  • [Cites] Diagn Cytopathol. 2005 Feb;32(2):65-9 [15637684.001]
  • [Cites] Diagn Cytopathol. 2005 Apr;32(4):204-10 [15754366.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):697-707 [16203289.001]
  • [Cites] Gut. 2000 Feb;46(2):244-9 [10644320.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2255-60 [11007226.001]
  • [Cites] Diagn Cytopathol. 1988;4(4):316-22 [3254809.001]
  • [Cites] Diagn Cytopathol. 1989;5(3):263-8 [2551616.001]
  • [Cites] Acta Cytol. 1989 Nov-Dec;33(6):936-9 [2686327.001]
  • [Cites] Diagn Cytopathol. 1989;5(4):388-91 [2612315.001]
  • [Cites] Diagn Cytopathol. 1989;5(4):408-11 [2612319.001]
  • [Cites] Am J Clin Pathol. 1990 Aug;94(2):142-9 [2164767.001]
  • [Cites] Radiology. 1991 Jan;178(1):253-8 [1984314.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):26-9; discussion 29-30 [1824810.001]
  • [Cites] Am J Clin Pathol. 1994 Apr;101(4):483-7 [8160642.001]
  • [Cites] Aust N Z J Surg. 1994 Jun;64(6):444-6 [7912067.001]
  • [Cites] Diagn Cytopathol. 1994;10(4):362-4 [7924811.001]
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):1-10 [7846994.001]
  • [Cites] Acta Cytol. 1995 Jan-Feb;39(1):23-7 [7847005.001]
  • [Cites] Gastroenterology. 1995 Apr;108(4):1230-5 [7535275.001]
  • [Cites] Acta Cytol. 1995 May-Jun;39(3):485-8 [7762337.001]
  • [Cites] Diagn Cytopathol. 1995 Mar;12(2):113-9 [7774489.001]
  • [Cites] Diagn Cytopathol. 1990;6(5):336-40 [1705496.001]
  • [Cites] Surg Gynecol Obstet. 1991 Sep;173(3):193-7 [1925879.001]
  • [Cites] Acta Cytol. 1991 Sep-Oct;35(5):546-8 [1927196.001]
  • [Cites] Diagn Cytopathol. 1991;7(4):341-5 [1935510.001]
  • [Cites] Diagn Cytopathol. 1992;8(1):65-7 [1551367.001]
  • [Cites] Acta Cytol. 1992 Jul-Aug;36(4):471-6 [1636336.001]
  • [Cites] Surgery. 1995 Sep;118(3):472-8 [7652681.001]
  • [Cites] Diagn Cytopathol. 1995 Aug;13(2):120-3 [8542789.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):233-46 [8575283.001]
  • [Cites] Acta Cytol. 1996 Mar-Apr;40(2):182-90 [8629395.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):470-4 [11275888.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):722-7 [11375578.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] Endoscopy. 2001 Oct;33(10):824-31 [11571676.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):106-12 [12004358.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):174-80 [12115306.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):291-6 [12145615.001]
  • [Cites] Cancer. 2002 Aug 25;96(4):232-9 [12209665.001]
  • [Cites] Acta Cytol. 2002 Sep-Oct;46(5):813-8 [12365212.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):325-34 [12451561.001]
  • [Cites] Cancer. 2002 Dec 25;96(6):362-9 [12478684.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):118-26; discussion 127-8 [12559193.001]
  • [Cites] Cancer. 2003 Feb 25;99(1):44-50 [12589645.001]
  • [Cites] Surgery. 2003 May;133(5):459-63 [12773972.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):341-8 [12789912.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):657-62 [12920762.001]
  • [Cites] Am J Clin Pathol. 2003 Sep;120(3):398-404 [14502804.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):723-6 [14526668.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):733-8 [14526670.001]
  • (PMID = 16698956.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 89
  • [Other-IDs] NLM/ PMC1860594
  •  go-up   go-down


84. Dawelbait G, Winter C, Zhang Y, Pilarsky C, Grützmann R, Heinrich JC, Schroeder M: Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data. Bioinformatics; 2007 Jul 1;23(13):i115-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data.
  • MOTIVATION: Pancreatic ductal adenocarcinoma (PDAC) eludes early detection and is characterized by its aggressiveness and resistance to current therapies.
  • RESULTS: Here, we take such a network-centric approach to pancreas cancer by re-constructing networks from known interactions and by predicting novel protein interactions from structural templates.
  • Our analysis indicates that the alteration of the calcium pathway plays an important role in pancreas-specific tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Gene Expression Profiling / methods. Models, Biological. Neoplasm Proteins / metabolism. Pancreatic Neoplasms / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646287.001).
  • [ISSN] 1367-4811
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


85. Gbelcová H, Lenícek M, Zelenka J, Knejzlík Z, Dvoráková G, Zadinová M, Poucková P, Kudla M, Balaz P, Ruml T, Vítek L: Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer; 2008 Mar 15;122(6):1214-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in antitumor effects of various statins on human pancreatic cancer.
  • The aim of the present study was to compare the effects of the individual commercially available statins on experimental pancreatic cancer.
  • The in vitro effects of individual statins (pravastatin, atorvastatin, simvastatin, lovastatin, cerivastatin, rosuvastatin and fluvastatin) on the viability of human pancreatic cancer were evaluated in CAPAN-2, BxPc-3 and MiaPaCa-2 cell lines.
  • In summary, substantial tumor-suppressive effects of various statins on the progression of experimental pancreatic adenocarcinoma were demonstrated, with marked differences among individual statins.
  • These results support greatly the potential of statins for the chemoadjuvant treatment of pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18027870.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  •  go-up   go-down


86. Recchia F, Sica G, Candeloro G, Bisegna R, Bratta M, Bonfili P, Necozione S, Tombolini V, Rea S: Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study. Pancreas; 2009 Aug;38(6):e163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
  • OBJECTIVES: The antitumor activity and toxicity of a multi-step treatment were evaluated in patients with locally advanced, inoperable, or incompletely resected pancreatic (Pa) and biliary tree (Bt) adenocarcinomas (ADKs).
  • [MeSH-major] Adenocarcinoma / therapy. Biliary Tract Neoplasms / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pancreas. 2012 Jul;41(5):825. Dosage error in published abstract; MEDLINE/PubMed abstract corrected
  • (PMID = 19531969.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; EH28UP18IF / Isotretinoin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


87. Tsutsumi K, Ohtsuka T, Oda Y, Sadakari Y, Mori Y, Aishima S, Takahata S, Nakamura M, Mizumoto K, Tanaka M: A history of acute pancreatitis in intraductal papillary mucinous neoplasms of the pancreas is a potential predictive factor for malignant papillary subtype. Pancreatology; 2010;10(6):707-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A history of acute pancreatitis in intraductal papillary mucinous neoplasms of the pancreas is a potential predictive factor for malignant papillary subtype.
  • The diameter of the main pancreatic duct of the pancreatitis group was significantly larger than that of the nonpancreatitis group (p = 0.04).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Pancreatitis / diagnosis

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21242711.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


88. Adhikari RC, Tuladhar A, Shrestha S, Sharma SK: Deep-seated thoracic and abdominal lesions: usefulness of ultrasound guided fine needle aspiration cytology, a 3 year experience. Nepal Med Coll J; 2010 Mar;12(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included liver (125 cases), lung (81 cases), abdominal and mediastinal lymph nodes (29 cases), ovary (14 cases), omentum (12 cases), pancreas (10 cases), kidney (10 cases), mediastinum (8 cases), gall bladder (8 cases) etc.
  • The aim of this study was to evaluate the overall utility of ultrasonographic guided FNAC in the diagnosis of abdominal and thoracic lesions.
  • In 264 cases (82.5%), FNAC was diagnostic with commonest diagnosis being malignant neoplasm (70.0%).
  • In liver, Metastatic adenocarcinoma is the commonest tumor, while in lung; the commonest lesion is non-small cell carcinoma.
  • [MeSH-major] Neoplasms / diagnosis. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677604.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


89. Newman EA, Simeone DM, Mulholland MW: Adjuvant treatment strategies for pancreatic cancer. J Gastrointest Surg; 2006 Jun;10(6):916-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment strategies for pancreatic cancer.
  • Pancreatic cancer is a difficult and unsolved surgical problem.
  • It remains one of the top five causes of cancer-related deaths and has the lowest 5-year survival of any cancer, largely due to late diagnosis, low resection rates, and local recurrence.
  • Clinical trials examining the optimal timing and delivery of adjuvant therapies for pancreatic cancer have yielded controversial results.
  • Although most experts agree that the addition of chemotherapy has survival benefit in patients with resectable pancreatic cancer, there is no consensus regarding the optimal therapeutic agents, timing (neoadjuvant versus adjuvant), and the addition of radiation therapy to the treatment regimen.
  • Additionally, exciting progress has been made with novel chemotherapeutic combinations, and alternative treatment modalities including interferon-alpha, immunotherapy, and pancreatic cancer stem cells.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Oct;52(4):578-82 [11023593.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):123-32 [11258776.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1528-35 [9427017.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4524-31 [16002843.001]
  • [Cites] Int J Pancreatol. 1991 Nov-Dec;10(3-4):183-96 [1787333.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Mayo Clin Proc. 1992 Sep;67(9):839-45 [1434927.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Ann Intern Med. 1989 May 1;110(9):704-9 [2930108.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):74-85 [12496533.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):766-72 [13129554.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):367-71 [10968852.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Pancreas. 1993 Mar;8(2):146-50 [8460088.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] J Gastrointest Surg. 2000 May-Jun;4(3):233-7; discussion 238-9 [10769085.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1685-95 [12365016.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] Radiother Oncol. 1992 Jul;24(3):191-4 [1357725.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2386-92 [15073115.001]
  • [Cites] Ann Surg. 1979 Feb;189(2):205-8 [426553.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1671-7 [8635074.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2317-23 [9840531.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):182-8 [11174289.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):224-9 [14760113.001]
  • [Cites] Cancer Biol Ther. 2004 Nov;3(11):1081-9; discussion 1090-1 [15467436.001]
  • [Cites] Surgery. 1999 Aug;126(2):178-83 [10455881.001]
  • [Cites] Cancer. 2002 Aug 15;95(4 Suppl):908-11 [12209670.001]
  • [Cites] Am J Gastroenterol. 1990 Apr;85(4):350-5 [2183589.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):459-67 [15905855.001]
  • [Cites] Eur J Cancer. 1993;29A(5):698-703 [8471327.001]
  • [Cites] J Gastrointest Surg. 2001 Jan-Feb;5(1):27-35 [11309645.001]
  • [Cites] Cancer. 1988 Mar 15;61(6):1110-6 [3342371.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1512-8 [11896099.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):145-56 [11134207.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1527-33 [10584796.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Feb;16(1):159-97, viii [12063825.001]
  • (PMID = 16769552.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 53
  •  go-up   go-down


90. Lee SE, Jang JY, Yang SH, Kim SW: Intraductal papillary mucinous carcinoma with atypical manifestations: report of two cases. World J Gastroenterol; 2007 Mar 14;13(10):1622-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1164-7 [11020905.001]
  • [Cites] Pancreas. 2006 Mar;32(2):223-4 [16552347.001]
  • [Cites] Surg Today. 2001;31(6):538-41 [11428610.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8 [12911716.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1323-4 [14535994.001]
  • [Cites] Endoscopy. 2004 Feb;36(2):186-9 [14765321.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):393-8 [15070599.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Pancreas. 2004 Apr;28(3):282-8 [15084972.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Gastroenterology. 1986 Jan;90(1):202-5 [2998918.001]
  • [Cites] J R Coll Surg Edinb. 1990 Feb;35(1):21-4 [2342004.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1636-40 [2208015.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1909-18 [8964418.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1010-7 [9308724.001]
  • [Cites] Pancreas. 1998 Jul;17(1):100-2 [9667528.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2009-15 [9951855.001]
  • [Cites] Pancreatology. 2005;5(4-5):470-4 [15983445.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):239-43 [11373099.001]
  • (PMID = 17461460.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4146910
  •  go-up   go-down


91. Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, Fischer SM: Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia; 2008 Aug;10(8):782-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.
  • We generated transgenic mice (BK5.COX-2) in which elevation of COX-2 and its effectors trigger a metaplasia-dysplasia sequence in exocrine pancreas.
  • By 6 to 8 months, strongly dysplastic features suggestive of pancreatic ductal adenocarcinoma emerge in the metaplastic ducts.
  • Alterations in biomarkers associated with human inflammatory and neoplastic pancreatic disease were detected using immunohistochemistry.
  • The abnormal pancreatic phenotype can be completely prevented by maintaining mice on a diet containing celecoxib, a well-characterized COX-2 inhibitor.